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Examining the mechanism of a Heavy-metal ABC Exporter 
Dennis Hicks 
ATP-Binding Cassette (ABC) Transporters are a superfamily of integral membrane 
proteins that have been found embedded in both the cellular membranes and internal organelles of 
all species yet analyzed (1). This extreme conservation throughout the tree of life is due to their 
vitally critical and broad task of transporting all manner of things into and out of the cell and 
related organelles. This broadness of responsibility has led to an abundant diversity of this family, 
which in turn, has allowed life to adapt to the many environments found on Earth. While the 
importance and variability of this family is abundantly clear, many mechanistic and regulatory 
questions remain. The diversity which has made this family so useful in the natural world has 
resulted in a huge challenge in the scientific world: elucidating the many mechanisms this family 
has developed to perform its many functions.  
The scientific community has so far been able to identify overarching features of all ABC 
transporters such as the Walker A and Walker B motifs (1); however, the mechanisms of individual 
transporters remain undiscovered. In my research, I focus on a specific ABC transporter called 
NaAtm1 (Novosphingobium aromaticivorans ABC transporter of mitochondria 1), which has been 
shown to mediate transition metal export in its host species (2). While some transition metals (e.g. 
iron and copper) are essential for certain cellular processes such as respiration and enzyme 
catalysis, other metals (e.g. cadmium and mercury) can be very toxic. Due to this extreme 
dichotomy, a cell’s ability to distinguish between friend and foe is of the utmost importance, and 
therefore is a highly regulated process.  
 
 
My goal during this program was to purify NaAtm1 and create a realistic in-vitro 
environment to analyze and better understand the full mechanism of this transporter, to determine 
why it exports some metals while leaving others alone, and to understand the regulatory processes 
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In this work, the methodology to reconstitute a purified ABCB-type ATP Binding 
Cassette transporter into a lipid bilayer mimetic environment is developed and optimized for use 
in kinetic studies. This chapter focuses on the history and importance of ABC transporters, 
transporter types and structure, as well as an overview of the protein of interest, NaAtm1. 
 
1.1 A Brief History of ABC Transporters 
The study of ABC transporters began in the late 1960’s with the study of membrane 
transport systems for the uptake of nutrients in the gram-negative bacteria E. coli. At this time, all 
cellular transport systems were known as permeases. Scientists divided this large group into two 
smaller classes: 1) osmotic shock-sensitive transport systems and 2) osmotic shock-insensitive 
transport systems. 
The process of osmotic shock was first described by Harold Neu and Leon Heppel in 1965. 
The process involves both a rapid change in the concentration of sucrose around a cell and the 
partial destruction of the outer membrane resulting in the release of periplasmic proteins. Briefly, 
gram-negative bacteria are placed in a solution that contains concentrated sucrose.  The sucrose 
draws water out of the cytoplasm shrinking the inner membrane and increasing the periplasmic 
volume while the addition of membrane-lysing enzymes and chemicals create holes in the outer 
membrane. The cells are then shifted to a solution containing no sucrose, which causes water to 
rapidly enter the inner cell. This increase in cytoplasmic volume results in the rapid reduction of 
periplasmic volume and pushes out many water-soluble periplasmic proteins through the lysed cell 




This technique of osmotic shock allowed scientists to develop the two-class theory of 
shock-sensitive and insensitive permeases. Further work on these two classes led to the discovery 
that the osmotic shock-sensitive nutrient permeases relied on a helper protein found solubilized 
within the periplasm [3, 4]. These proteins shepherded nutrients to their respective transporters 
found on the inner membrane and were later named substrate binding proteins (SBPs). It was the 
resulting absence of these proteins from the expulsion of the periplasm during osmotic shock 
which gave this class its name. Research also showed that this class of transporter directly derived 
their energy from adenosine triphosphate (ATP) instead of from a concentration gradient, as is the 
case with the osmotic shock-insensitive transport class [5]. This osmotic shock-sensitive class 
would later become known as ATP-Binding Cassette (ABC) transporters.  
By the early 1980’s, scientists had started cloning many genes that encoded for this class 
of transporter; most notably the maltose transporter found in E. coli [6] and the histidine transporter 
of S. Typhimurium [7]. At the same time, other researchers were looking into why some 
mammalian cell lines –particularly certain cancer cell lines– had the unique ability to resist a wide 
range of chemotherapy drugs. In 1976, researchers in Toronto discovered a large membrane 
protein that was found in abundance in mammalian cells that were multi-drug resistant (MDR), 
but not found in the corresponding wild-type cells (Figure 1-1). This protein was named 
permeability glycoprotein (P-gp) [8] due to its ability to modulate drug permeability. Not long 
after this discovery, P-gp was successfully cloned [9] and its amino acid sequence compared to 
that of other transport proteins, both bacterial and mammalian.  
The comparisons showed that sequences from certain sections of many transport proteins 
were highly conserved. Two of the most highly conserved sequences are known as the Walker A 




[10]. These two motifs were determined to be involved in the binding and catalysis of ATP, 
respectively, and were the first hints at a very distant common ancestor, both among ABC 
transporters and ATP-requiring enzymes in general. Further comparisons between mammalian and 
bacterial transport proteins showed that these transporters were part of a large and diverse family 





Figure 1-1. Timeline of ABC transporter research reproduced from Theodoulou et al. [15]. Notable discoveries include 
the identification of P-gp in 1976 and the cause of CFTR mis-localization (F508Δ) in 1992. 
 
 
With the help of cutting-edge technologies such as genetic sequencing, X-ray 
crystallography, genomic libraries, and computer data analysis and modeling, the 1990’s and early 
2000’s saw an explosion of new data and discoveries regarding this family (Figure 1-1). While 




transporters, many questions remain unanswered. Most studied topics relating to ABC transporters 
include substrate affinity, cycle mechanisms, intra-protein and protein-protein interactions, and 
transporter kinetics. These topics are of immense interest, not only for their intellectual value, but 
also their practical application for human health. 
 
1.2 ABC Transporters in human health 
1.2.1 Multi-drug resistant (MDR) abilities in cancer and bacteria/fungi 
It was clear early on that at least one ABC 
transporter, P-gp, played a major role in multi-drug 
resistant cancers within mammals (Figure 1-2). P-gp, 
also known as multidrug resistant protein 1 (MDR1), 
has been shown to export a wide variety of xenobiotics 
from human cells, including pharmaceutical drugs [18]. 
While cancer cells may be sensitive chemotherapeutics, 
cells that overexpress P-gp can extrude these toxic 
drugs, lowering the intracellular concentration and 
ultimately rendering the drug ineffective. These cancer cells over-expressing P- gp are rendered 
multidrug resistant.  
 
While P-gp was first found in Chinese hamsters [8], homologs have been found in both 
bacteria and fungi as well [17, 18]. Due in part to the over-prescription of antibiotics and the failure 
of patients to use them correctly, many strains of bacteria and fungi have been able to develop their 
own version of P-gp and other MDR transporters to remove a staggeringly wide range of 
            
Figure 1-2. Structure of P-gp as reported by 
Aller et al. [16]. The red portion 
represents the component of P-
gp surrounded by a lipid bilayer. 




antibiotics, making the infections they cause virtually untreatable. Many scientists fear that we are 
fast approaching the “post-antibiotic” era; a time at which all current antibiotics will no longer be 
effective [20]. Along with antibiotic resistance, MDR presents a major hurdle in the development 
of antivirals, antiparasitics, and antifungals. Fortunately, the study of ABC transporters offers a 
possible solution to this challenging scenario. If scientists can elucidate the mechanisms of these 
MDR transporters, they might also find a way to disable them.  
 
1.2.2 Human ABC Transporter Related Diseases 
While multi-drug resistant infections are of great importance to human health, so too is the 
study of human ABC transporters. So far, about 50 human ABC transporters have been discovered 
[21]. Of these, 14 have been shown to cause 13 different diseases (Table 1-1), the most notable 
being cystic fibrosis.  
Cystic fibrosis is caused by a point mutation in the ABCC7/CFTR transporter that is 
involved in chloride ion transport in epithelial cells that are part of mucous membranes. These 
membranes are abundant in the lungs, pancreas, and liver. When functioning normally, the 
ABCC7/CFTR protein transports chloride ions to the cell surface. The chloride ions attract water 
which results in a less viscous mucus that can be cleared from the lungs by cilia also located on 
the cell surface. When the ABCC7/CFTR protein is mutated, chloride ions are unable to be 
transported to the cell surface, resulting in less water accumulation and a thick mucus that is unable 
to be moved by cilia and therefore accumulates within affected organs.  
Symptoms of cystic fibrosis include mucus with an abnormal viscosity and sweat with a 








Table 1-1. List of current known diseases in which ABC transporters play a role [21]. Most notable diseases are 
cystic fibrosis and Stargardt disease, caused by damaged ABCC7 and ABCA4 transporters respectively. 
 
 
By understanding how these transporters work and what mutations in their structure lead 
to their dysfunction, scientists may one day be able to repair them through gene editing. While this 
technology is still in the very early stages of development, it has been used to treat cystic fibrosis 




1.3 Challenges in organizing the ABC transporter family 
The ABC transporter superfamily is one of the largest and most diverse families of protein 
in existence. They have been found embedded in both the cellular membranes and internal 
organelles of all species yet analyzed [24]. This extreme conservation throughout the tree of life is 
due to their vitally critical and broad task of transporting an extensive collection of molecules into 
and out of the cell and related organelles. This broadness of responsibility has led to an abundant 
diversity within this family, which in turn, has allowed life to adapt to the many environments 
found on Earth. This same diversity has also posed an immense challenge to those seeking to 
organize such a complex group of proteins for the purpose of making connections between 
individual transporters and gaining significant insights regarding transporter form and function. 
Before organization can begin, one needs first to understand the components that make up ABC 
transporters. 
 
1.4 Basic structure and components of ABC transporters 
 The typical ABC transporter consists of four core domains: two transmembrane domains 
(TMD1 and TMD2) and two nucleotide binding domains (NBD1 and NBD2). These domains can 
be connected in many different combinations (Figure 1-3). They can be found as four separate 
subunits (tetramer), a heterodimer or homodimer consisting of one TMD and one NBD per subunit 
(also known as a “half” transporter), a trimer consisting of a subunit containing two NBDs and 
two TMD subunits, or a single polypeptide chain containing all four subunits [25]. While all ABC 
transporters must include these four domains, some also include additional components, most 





Figure 1-3. Various domain combinations reproduced from the HDL Handbook (Third Edition) [26]. As a rule, tetramers 
and trimers are only found in bacterial ABC transporters while eukaryotic ABC transporters are made up 
of either dimers or monomers.  
 
 
In the following figures, the high-resolution x-ray crystallography structure of the NaAtm1 
transporter is used as an example to highlight the basic domain architecture of ABC transporters 
(Figure 1-4) . This transporter is the focus of this thesis, and its characteristics are explained in 
greater detail at the end of this chapter.  
 
 
Figure 1-4. TMDs and NBDs of NaAtm1 as reported by Lee et al. [33] NaAtm1 is a homodimer, with each monomer 





1.4.1 The transmembrane domains (TMDs) 
Transmembrane domains form the translocation pathway for substrates to move through 
the membrane and are typically comprised of between 5 and 10 amphipathic helices per subunit 
(10-20 helices total) [24]. This pathway is only open to one side of the membrane at a time and 
access to the pathways interior is alternated through the binding and hydrolysis of ATP in the 
nucleotide binding domains (NBDs).  
The NBDs drive the conformational change in the TMDs through a coupling helix – a short 
alpha helix found on the cytosolic side of each TMD (Figure 1-5). This coupling helix fits into a 
groove in the neighboring NBD and allows for the transfer of energy to induce the conformational 
change in the TMD [27]. While these coupling helices differ depending on the class of ABC 
transporter, in most cases each TMD is connected to one NBD resulting in two coupling helices 
per transporter. 
The TMDs of ABC transporters are extremely diverse but usually share a similar topology 
within the same class [28]. This diversity is most likely due to the wide array of substrates 
transported by ABC transporters.  
 
 
1.4.2 The nucleotide binding domains (NBDs)  
The nucleotide binding domains (NBDs) are also known as ATPase domains or ATP 
Binding Cassettes and give this class of transporter its name [29]. They drive the conformational 
change needed to translocate substrates across a membrane through the binding and hydrolysis of 





There are always two nucleotide binding domains (NBD1 and NBD2) found within an 
ABC transporter, with each domain consisting of two subdomains. These subdomains consist of a 
RecA-like domain (found in other ATPases) and an alpha-helical domain (found only in ABC 
transporters). Each subdomain in an NBD contributes to one aspect of the reaction (binding or 
hydrolysis) and can only couple with the opposite subdomain on the corresponding NBD (Figure 
1-5C). The functional nucleotide binding sites are located at the interface between these two 
opposing subdomains. 
   
 
Figure 1-5. A) Crystal structure of NaAtm1 as reported by Lee et al. [31]. B) A simplified diagram of NaAtm1showing 
the four domains and coupling helices (unlabeled circles). C) A top-down view the two NBDs of NaAtm1 
showing the RecA-like and α-helical subdomains. 
 
 
Although there are always two NBDs and two ATP binding pockets, it is not always the 
case that a transport cycle requires two ATP molecules. For example, while the OpuA transporter 
hydrolyzes two molecules of ATP per substrate molecule [32], only one functioning active site is 
enough to drive transport by TAP1. Interestingly, TAP1 contains a naturally occurring mutation 
that results in one degenerate ATP binding site [33]. Additionally, when one site is artificially 




While the transmembrane domains of this family are diverse, the nucleotide binding 
domains show very high conservation. There are seven highly conserved amino acid 
sequences/motifs in NBDs that allow for the identification of ABC transporters, as described 
below. Of these seven, only the C Motif (ABC signature motif) is located in the α-helical domain; 
the other six are located in the RecA-like domain. In the case of the target protein NaAtm1, all 





Figure 1-6. Crystal structure diagram top-down view of the NBDs of NaAtm1 [31]. Each NBD contains one RecA-like 
domain and one α-helical domain. Each RecA-like domain contains a Walker A motif (yellow), Walker B 
motif (pink), A-Loop (black), D-Loop (red), H-Loop (magenta), and Q-loop (blue). Each α-helical domain 
contains the C motif (cyan). When ATP binds on the RecA-like domain (red circle) and a substrate binds in 
the substrate binding pocket (not shown), a conformational change takes place causing the α-helical domain 
on the opposite NBD (blue circle) to move toward the RecA-like domain, sandwiching the ATP between the 





1.4.2.1 Walker A Motif (P-loop) 
The Walker A motif connects an α-helix and a ß-strand to form a pocket for ATP binding 
within its NBD [35]. The consensus sequence for this motif varies slightly depending on the 
source. The most common sequences are GXXXXGKS [36], GXXGXGKS [37], 
(G/A)XXXXGK(T/S) [10], and GXXGXXK [38]. The X residues in these sequences signify highly 
variable amino acids.  
The most highly conserved residues in this motif are the N-terminal glycine and the C-
terminal lysine. The lysine has been shown to bind to the γ-phosphate of ATP and in some cases 
is replaced by an arginine which can lower the activity [39]. A serine or threonine usually follows 
the highly conserved lysine and provides a hydroxyl group to bind the divalent cation associated 
with the bound nucleotide [40]. In NaAtm1, this sequence starts at residue 349 and ends at 401 




Figure 1-7. Cartoon diagram side view of the NaAtm1 Walker A motif (yellow) with the highly conserved residues 






1.4.2.2 Walker B Motif 
The Walker B motif coordinates the magnesium ion needed for catalysis. This ion interacts 
with the ß- and ɣ- phosphates of ATP and helps to both stabilize and hydrolyze ATP. The general 
consensus sequence for this motif is hhhhD(E) and consists of three components: four hydrophobic 
residues (h) followed by an acidic negatively charged residue (usually aspartic acid) and then a 
second acidic residue (usually glutamic acid). The second acidic residue (E) is commonly included 
in the D-loop conserved sequence which immediately follows the Walker B motif. The aspartic 
acid is believed to play a role in coordination of the magnesium ion while the acidic residue 
immediately following it acts as a general base, polarizing an attacking water molecule involved 
in the hydrolysis of the ɣ- phosphate in ATP [41]. In NaAtm1, this sequence starts at residue 518 







Figure 1-8. Cartoon diagram side view of the NaAtm1 Walker B motif (pink) with the highly conserved residue aspartic 







The A-loop is composed of a single aromatic residue that helps position the ATP through 
stacking with the adenine ring of ATP [42]. This residue generally appears around 25 amino acids 
upstream from the Walker A motif. In NaAtm1, the A-loop consists of a tyrosine 24 AA upstream 






Figure 1-9. Cartoon diagram side view of the NaAtm1 A-loop (black) with the aromatic residue tyrosine (D522) as 








1.4.2.4 C Motif (ABC signature motif) 
This sequence is a signature of ABC transporters and is not found in other P-loop NTPases 
and has a consensus sequence of LSGGQ. It is found in the α-helical subdomain and has been 
shown to interact with the RecA-like domain on the opposing NBD to form a binding pocket. The 
serine (S499) in this motif interacts through its oxygen with the ɣ- phosphate of ATP [43]. This 
interaction may draw these two subunits together causing a conformational change in the NBDs 
(going from an open position to a closed position) which results in a conformational change of the 
TMDs.  In NaAtm1 this sequence starts at residue 498 and ends at 502 (Figure 1-10). This motif 






Figure 1-10. Cartoon diagram side view of the NaAtm1 C Motif (cyan) with the active residue serine (S522) as reported 











The D-loop is a sequence that immediately follows the Walker B motif and has a consensus 
sequence of SALD or EATSALD (overlapping Walker B) depending on the source. In the 
EATSALD sequence, the E corresponds to the second acidic residue in the Walker B motif, 
glutamate. While this glutamate is involved in polarizing the catalytic water molecule in the active 
site, the aspartic acid on the opposite end (D529) interacts with the P-loop (Walker A Motif) of 
the opposing active site [44]. This interaction between the D-loop on one NBD and the P-loop of 
the opposite NBD is believed to allow communication between the two active sites [45, 46]. In 







Figure 1-11. Cartoon diagram side view of the NaAtm1 D-loop (red) with the active residues glutamic acid (E523) and 









The H-loop consists of a highly conserved histidine residue that forms a “hinge” or “lynchpin” 
between an α-helix and a ß-sheet. Until recently, it was thought this residue acted as a non-reactive 
“lynchpin” that only coordinated the aspartate at the end of the D-loop, the glutamate at the 
beginning of the D-loop/end of the Walker B motif, the ɣ- phosphate on ATP, and the magnesium 
ion through hydrogen bonding. New research suggests however that this residue also acts as a 
proton transfer point by acting first as a general acid, and then as a general base during ATP 






Figure 1-12. Cartoon diagram side view of the NaAtm1 H-loop (magenta) with the highly conserved residue histidine 








The Q-loop consists of a highly conserved glutamine found at the junction of the two NBD 
subdomains and has the consensus sequence XXQXX where X represents any amino acid. The Q-
loop is the main interface between the NBD and TMD and its conformational changes allow the 
conserved glutamine to form an active site when ATP is bound and to disrupt the active site when 
ATP is hydrolyzed [29]. In NaAtm1 this sequence starts at residue 440 and ends at 444 (Figure 1-







Figure 1-13. Cartoon diagram side view of the NaAtm1 Q-loop (blue) with the highly conserved residue glutamic acid 








1.5  Accessory Domains 
Accessory domains are transporter components that are not ubiquitous to all transporters -
indeed, the protein of interest in this thesis, NaAtm1, contains none of these- but when present, 
play an important role in protein function. These domains can be found separate from, attached to, 
or integrated in a transporter. These domains have been divided into four categories based on 
location and function [48]. They are: extracytoplasmic domains, membrane-embedded domains, 
cytosolic regulatory domains, and cytosolic catalytic domains.  
 
1.5.1  Extracytoplasmic domains 
 These domains are found on the N-terminal (extracellular) end of transporters or in the 
periplasm. There are three subgroupings of this domain: large extracytoplasmic domains (ECDs), 
the N-terminal domains of ProW and ProU, and the substrate binding proteins (SBPs) found in 
prokaryotes [48]. For purposes of simplicity, only substrate binding proteins (SBPs) will be 
discussed in this paper.   
 ABC transporters that import substrates require Substrate Binding Proteins (SBPs) to act 
as substrate shepherds. These proteins capture substrate and deliver it to the cytoplasmic side of 
the TMDs. SBPs can be tethered to the ABC transporter, anchored to the membrane, or free 
floating in the periplasm (only found in gram negative bacteria). These proteins have been shown 
to be monomers with one binding site per SBP [49]. 
 SBPs are generally composed of two lobes connected by hinge (although there are three-
lobed SBPs, of which the third lobes function is not known [50]) (Figure 1-14). This hinge allows 
the two lobes to enclose a substrate similar to the way a Venus flytrap catches its prey [51]. The 







Figure 1-14. Crystal structure of the substrate binding protein (SBP) BtuF with vitamin B12 bound as reported by Borths 
et al. [52]. The two lobes (blue and red) are attached to a hinge (green) that allow them to enclose the 
substrate vitamin B12. 
 
 
1.5.2  Membrane-embedded domains 
 This set of accessory domains consists of the extra transmembrane helices seen in many 
transporters that are not part of the “core” TMDs (i.e. helices that do not help form a translocation 
pathway). While the function of many of these are unknown, some are proposed to act as anchors 
for SBPs [53].  
 
1.5.3  Cytosolic regulatory domains 
These accessory domains are found on the cytosolic side of the membrane and are used to 
regulate the activity of the transporter as well as transcriptional regulation. The mechanisms of 
regulation vary by transporter and type of regulation. These regulations allow for the fine tuning 
of nutrient uptake or product/waste expulsion within a cell. An example of this regulatory domain 
can be found within the methionine importer of E. coli, MetNI. In this importer, methionine is both 







1.5.4  Cytosolic catalytic domains 
In some cases, the accessory cytosolic domain has a catalytic purpose. In the type I 
secretion pathway, ABC transporters not only transport polypeptides targeted for export but have 
the additional job of removing the leader peptides that denoted export as well. The signal sequence 
in this case has a consensus sequence of LSXXELXXIXGG and is cleaved after the two conserved 
glycine residues [54]. 
 
1.6  ABC transporter classes  
The superfamily of ABC transporters is just that – a superfamily – and it can be a challenge 
to divide such a large and diverse set of proteins. While all ABC transporters contain a core of four 
domains (two NBDs and two TMDs), their cellular function allows for broad categorization. To 
start, we can differentiate between importers, exporters, and non-porters. These groupings can be 
further subdivided through structural homology, sequence similarity, and functional similarity. 
 
1.7  ABC importer classes and proposed mechanisms 
 ABC importers are a group of ABC transporters that, as the name suggests, bring needed 
materials into a cell and, with very few exceptions, are only found in bacteria and archaea [55]. 
Substrates include sugars, peptides, proteins, sterols, lipids, and ions. The majority of these 
importers require a substrate binding protein (SBP) to function properly (part of the 
extracytoplasmic accessory domains as described above). These SBPs led to the discovery of this 
family (part of the osmotic-shock sensitive transport systems as described in the introduction). In 
this class, the four core domains are only found as either a tetramer (as in the Nik, Mal, and Btu 




15) [48]. Importers can also be subdivided based on their functionality into three subgroups: Type 




Figure 1-15. Cartoon drawing of the different core arrangements for the importer class of ABC transporter adapted 
from Biemans-Oldehinkel et al. [48]. 
 
1.7.1  Structure of Type I and II importers 
 While these two types of importer are very similar in terms of composition and topology, 
structural and mechanistic features divide them into two separate groups. Structurally, Type I 
importers have a core of 5 transmembrane helices per TMD and commonly contain additional 
TMD helices that wrap around its partner TMD (10-16 helices total, see Figure 1-16) [29]. The 
two TMDs of the Type I importer face each other and the translocation pathway is found between 
them. Type II importers have 10 helices per TMD (20 total), and do not contain any helices that 








Figure 1-16. Top-down view of the TMDs from a Type I and Type II importer. A) MalF and MalG TMD subunits of the 
Type I transporter MalEFGK2 [56]. B) BtuC dimer of the Type II transporter BtuC2D2F [57]. 
 
In addition to the different TMD arrangements, Type I importers such as MalFGK2 contain 
a substrate binding site within their TMDs (not to be confused with a Substrate Binding 
Protein) while Type II importers do not. This is probably due to the types of substrates each 
importer type transports as well as potential mechanistic differences between the two. Type I 
importers generally only handle small molecules such as ions, small peptides, amino acids, and 
mono-/oligosaccharides [58]. It is possible these small molecules have more room to move (and 
escape) while in the translocation pathway, and the presence of a substrate binding site ensures 
that the transport process is efficient by providing a checkpoint for regulation; if no substrate is 




handle large complex molecules such as vitamin B12 and heme, as well as inorganic ions [58] 
which may have a lesser chance of escaping the translocation pathway.  
Both the Type I and Type II importers contain an extracytoplasmic accessory domain: a 
substrate binding protein (SBP) to shepherd substrates to their N-terminal openings. These 
domains can be soluble within the periplasm (found in gram-negative bacteria), attached to the 
cytoplasmic membrane either by a “lipid anchor” (gram-positive bacteria) or a transmembrane 
peptide (archaea), or directly fused to one of the TMDs (resulting in two SBPs per importer) [48] 
(Figure 1-17).  In the glutamine-glutamate transporter system, GlnPQ, two SBPs are fused to a 
single TMD resulting in four SBPs per importer [59].  
 
 
Figure 1-17. Cartoon drawing of the different types of Substrate Binding Proteins (SBPs) reproduced from Biemans-




1.7.2  Possible mechanisms of Type I and II importers 
  While these two importer types contain similar core domains along with an SBP, an 
increasing number of studies have demonstrated a diversity of transport mechanisms. The two 





An impressive body of structural studies on the maltose transport system (MalFGK-E) and 
vitamin B12 system (BtuCD-F) has provided evidence in support of an alternating access model for 
transport [60 and 61]. In this model there are four general steps in the catalytic cycle, however 







Figure 1-18. The alternating access model for transport. This process starts at the center top and moves clockwise.  
 
 
The cycle starts when a ligand-loaded substrate binding protein binds to the TMDs of the 
transporter that is in a “resting state” (referred to as the “inward facing conformation”) with the 
energy source ATP absent from the ATP active sites (Figure 1-18, top). The binding of the ligand-




of ATP triggers coordinated conformational changes in the TMDs, SBP and NBDs. In the TMDs, 
the conformational change results in opening of the translocation pathway to the periplasm (the 
“outward facing conformation”). In the SBP, the conformational change of the TMDs result in the 
release of the ligand into the translocation pathway, where the ligand binds to the substrate binding 
site. In the NBDs, the ATP-filled active sites come close enough for hydrolysis to occur. In the 
third step ATP hydrolysis occurs; the hydrolyzed ATP (now ADP and Pi) cause the transporter to 
return to the resting state (inward conformation) which results in the opening of the NBDs, release 
of the ligand into the cytosol, and the release of the now empty SBP. The fourth step consists of 






Figure 1-19. A second model for transport, based on the vitamin B12 importer, BtuCD-F [58]. 
 
 
A second “non-canonical” mechanism for transport is based on functional assays and, most 
recently, mass spectrometry [58, 62, 63]. In this model, the cycle starts with the transporter in a 
resting state (partially outward conformation) with no ATP bound and the substrate binding protein 
firmly bound (Figure 1-19, top). The binding of one ATP molecule increases the affinity of a 
second ATP binding and the presence of two ATP molecules partially destabilize the SBP by fully 
opening the TMD (outward conformation). This destabilization allows for the ligand to fit in 




substrate binding site, the partial insertion of the ligand into the translocation pathway results in 
the NBDs coming close enough for hydrolysis to occur. The hydrolysis results in the opening of 
the NBDs (inward conformation), release of the substrate, and the re-binding of the SBP [58]. The 
now-hydrolyzed ATP (ADP + Pi) are then released and the cycle is reset.  
Interestingly, both of these models have been developed based on work from the same 
transport systems, mainly MalFGK-E and BtuCD-F. Support for the alternating access model is 
driven by the high-resolution crystal structures of several intermediate states throughout the 
transport cycle. The non-canonical model, in contrast, is based on functional studies including 
thermodynamic, kinetic, and mass spectrometry experiments. The techniques and experimental 
conditions for these studies are fundamentally different, and their conflicting conclusions remain 
to be resolved.    
 
 
1.7.3  Structure of Type III (ECF) importers 
If the Type I and II importers are considered fraternal twins, the Type III importer can be 
considered the weird younger brother who may or may not be the milkman’s. This class of 
transporter is also known as an energy coupling factor (ECF) type ABC transporter. While the 
Type I and II importers have a pair of transmembrane domains that form a translocation pathway 
for the substrate, Type III importer architecture is significantly different. Type III importers consist 
of two distinct integral membrane proteins: (1) a substrate-binding component (or S-component) 
with high substrate specificity and (2) a transmembrane component (or T-component) that 
transfers the energy from the NBDs [64]. The three-component complex consisting of the T-




into two subgroups based on chromosomal location of the genes that encode these two 
components: ECF group I and ECF group II [65]. 
 
1.7.3.1 Differences between ECF subgroups I and II 
 Members of the ECF group I importers have genes that code for the S-component and ECF 
module on the same operon which are thought to form a dedicated complex (i.e. a complex that 
does not dissociate). In contrast, members of the ECF group II have genes for the ECF module 
separate from multiple S-components that have different substrate specificities. These S-
components are thought to form interchangeable complexes with a single ECF module. This 
modular system is an interesting departure from the Type I and Type II import systems and 
potentially streamlines the number of protein components needed for uptake of different 
substrates.   
 
1.7.3.2 Type III substrates 
 The Type III importers have been shown to have high specificity for vitamins or vitamin 
precursors including pantothenate, pyridoxine, thiamine and its precursors, methionine, cobalamin 
precursors, queuosine, lipoate, niacin and folate [65]. In total, the S-components have been 
classified into 21 protein families, which are associated with either ECF group I or group II T-








Figure 1-20. A list of known dedicated (green) and shared (pink and tan) Type III ECF transporters (bold) and their 
substrates [65].  
 
 
1.7.4  Type III transport mechanism 
What is truly unique about this transporter is the movement of the S-component within the 
lipid bilayer. Crystal structures have shown that while solitary S-components have substrate 
binding sites close to the extracellular side of the membrane, the S-component can lie parallel to 
the lipid bilayer with its binding site exposed to the cytosol when in complex with the ECF module. 







Figure 1-21. A proposed mechanism for the ECF-type transporter [61]. 
  
This mechanism varies slightly between Group I and Group II proteins only in that the S-
component is interchangeable in group II. The first step in the Group II mechanism is the joining 
of a ligand-bound S-component and a free ECF module into a full complex. 
 
1.8 ABC exporters 
 ABC exporters are found in all lifeforms yet studied. They are located on the cellular 
membrane of both prokaryotic and eukaryotic species as well as in organellar membranes of 
eukaryotic species including the ER, inner mitochondrial membrane, peroxisomal membrane, and 
vacuolar membrane [48]. ABC exporters do not require a SBP to function as is the case with the 
Type I and II importers. While many importers are found a tetramers or trimers, ABC exporters 
are almost exclusively found as “half transporters” (a pair of polypeptides that each contain one 
TMD and one NBD) or “full-length transporters” (a single polypeptide containing two TMDs and 
two NBDs).  
 As previously stated, ABC importers are, with very few exceptions, found only in 
prokaryotic life. This means that eukaryotes only possess ABC exporters and therefore the exporter 
group of ABC transporters is usually referred to as the eukaryotic group of ABC transporters, even 




seven families based on domain organization and primary structure similarity [66]. These families 
are ABCA, ABCB, ABCC, ABCD, ABCE, ABCF, and ABCG. For simplicity, the descriptions 
below focus on the human members of these families.  
 
1.8.1  ABCA Transporters 
 The ABCA family was first described in 1994 by Luciani et al. [67] and consists of twelve 
known members in humans. This group of transporters has been shown to be involved in lipid 
transport and some members are hypothesized to be involved in pulmonary surfactant secretion 
and macrophage lipid homeostasis.  
 
1.8.2  ABCB Transporters 
 The ABCB family consists of eleven known members, seven of which are “half 
transporters” and is the only family that contains both “half transporters” and “full transporters”. 
This family contains the most famous of human ABC transporters – ABCB1. This transporter, 
more commonly known as P-gp, acts as a localized general drug exporter and confers multi-drug 
resistance (MDR). Some members of this family participate in the secretion of 
phosphatidylcholine, cholesterol, and bile salts, while others are found in the mitochondria and are 
involved in iron/sulfur synthesis and transport [66]. 
 
1.8.3  ABCC Transporters 
  This family contains twelve known human “full transporters” which are involved in drug 
resistance, ion transport, nucleoside transport, and signal transduction. The most highly-studied 




transporter acts as a chloride ion channel and results in cystic fibrosis when deformed or absent. 
While there are many mutations that cause the CFTR protein to fail, the majority of those suffering 
from cystic fibrosis have a mutation that causes misfolding in the protein that keeps it from 
localizing to the cell surface.  
 
1.8.4  ABCD Transporters 
 This family contains four genes that encode “half transporters”, all of which are expressed 
only in the peroxisome. Recent studies suggest that these subunits can mix and match and might 
be linked to fatty acid metabolism. It has been shown that ABCD1 plays a role in the X-linked 
form of adrenoleukodystrophy (ALD) which is characterized by cells with an excess of unbranched 
saturated fatty acids [66].  
 
1.8.5  ABCE Transporters 
 There is currently only one human member of this family: ABCE1. It is considered a non-
porter due to the absence of a transmembrane domain. It is made up of two NBDs and an N-
terminal Fe-S binding domain. This protein inhibits a nuclease induced by interferon in 
mammalian cells. It also has been shown to play a role in vertebrate translation initiation. ABCE1 
is found in all characterized eukaryotes and archaea [68]. 
 
 
1.8.6  ABCF Transporters 
 There are three known human genes that encode 26 different known proteins for this 
family. Like the ABCE transporters, these proteins lack any TMDs and are considered non-porters. 





1.8.7  ABCG Transporters 
 This transporter class is unique in that it contains five genes that encode six reverse “half 
transporters”. These subunits contain a NBD at the N-terminus and a TMD and the C-terminus—
the reverse of all other ABC genes. This family was first reported in Drosophila White (white-
eyed mutant fruit fly) and is known as the “White Half Transporters” [70]. In Drosophila White, 
this first protein (white) found in white-eyed males can combine with two other proteins (brown 
and scarlet) to form heterodimers which transport guanine and tryptophan respectively to the eye 
cells and result in the eye color. While these proteins play a role in eye pigment in flies, in humans 







1.8.8  Proposed mechanism of exporters 
 The proposed general mechanism for exporters is similar to that of the canonical alternating 
access model (Figure 1-22). In the case of exporters, the resting state is in an inward conformation. 
The substrate binds at a substrate binding site in the TMDs, followed by the binding of two ATP, 
or vice versa. The binding of substrate and ATP triggers a conformational change in the TMDs to 
the outward conformation. The substrate is released to the exterior of the cell, and ATP is 
hydrolyzed. The hydrolysis of the ATP resets the transporter back to the resting state [72].  
 
 







1.9 ABC non-porters 
 Some proteins that contain both the Walker A and B motifs, as well as the ABC signature 
motif are known to carry out other functions than transport. These types of “transporters” usually 
do not contain a transmembrane domain such as the members of the eukaryotic groups ABCF and 
ABCG. Many of these proteins such as Rad50 play a role in regulation and DNA repair [73]. Due 
to the non-transporter-like nature of these proteins, they will not be discussed in depth. 
 
1.10  Protein of interest: an ABC exporter found in mitochondria 
This thesis focuses on a member of the ABCB exporter family found in mitochondrial 
membranes. The first homolog of this exporter was discovered in the inner membrane of 
mitochondria of Saccharomyces cerevisiae and was named Atm1p (ABC transporter of 
mitochondria 1) [74]. Initial studies of Atm1p showed that the disruption of this transporter in vivo 
led to very slow growth on rich media and no growth on minimal media. Further experiments with 
Atm1p showed that the mitochondria lacked mature cytochromes (i.e. cytochromes that contained 
a covalently bonded heme group) and that heme-containing proteins outside the mitochondria were 
also affected in the same way. After ruling out other factors such as impaired heme attachment 
reaction pathways and biosynthetic pathways, it was determined that Atm1p plays a critical role 
in the maturation of heme-containing proteins within the cell [75]. 
Researchers then looked for what substrates might be transported by Atm1p and found that 
in mitochondria that lacked functioning Atm1p, their “free” iron (iron not bound to heme or Fe-S 
clusters) was 30 times greater than that of wild-type mitochondria. Of this, only a small fraction 
was in a state that could be readily used for the synthesis of heme and Fe-S clusters. This suggested 




might be a natural substrate [75]. While the identity of Atm1p’s natural substrate remains unclear, 
likely candidates include Fe-S complexes and heme (or some intermediate). The creation of these 
cytosolic heme and iron sulfur cluster containing proteins are critical in many cellular processes 
such as DNA synthesis and respiratory electron transfer chains. Due to this role in the maturation 
of iron-containing proteins that are essential to cellular function, this is the only known eukaryotic 
ABC transporter that is essential for cell growth [75]. 
Atm1p homologs have since been characterized in several other species, including ABCB6 
and ABCB7 in humans and HMT1 in multiple species. In humans, the ABCB7 transporter plays 
a role in transition metal homeostasis and iron-sulfur cluster maturation in the cytosol [76] while 
the ABCB6 transporter may play a role in arsenic resistance [77]. When ABCB7 is damaged, it 
results in X-linked sideroblastic anemia which is associated with spinocerebellar ataxia 
accompanied by severe cerebellar hypoplasia [78]. In both C. elegans and D. melanogaster, HMT1 
confers resistance to cadmium [79, 80].  
In many of these homologs, the polypeptide glutathione (GSH, γ-Glu-Cys-Gly) has been 
shown to play a role in transport of substrates (Figure 1-23) [81], although the mechanism of this 
dependence is unclear. Glutathione is a key antioxidant and helps confer resistance to heavy metals 
and xenobiotics [82, 83] so it is plausible that GSH acts as a co-substrate for Atm1p homologs, 
with an affinity for a wide array of toxic materials as well as the ability to stimulate these 
transporters.  
 




1.10.1 Atm1 in Novosphingobium aromaticivorans 
The focus of this work is on the Atm1p homolog 
found in Novosphingobium aromaticivorans 
(Novosphingobium aromaticivorans ABC transporter of 
mitochondria 1). This species was first classified by 
Takeuchi et al. in 2001 [84] and is an aerobic gram-negative 
bacterium that can break down phenolic structures. It has 
also been implicated in biliary cirrhosis in humans due to its 
ability to express proteins similar to human proteins that 
trigger T cell-mediated tissue destruction [86].   
NaAtm1 was structurally and functionally characterized by Lee et al. in 2014. The high-
resolution crystal structure of NaAtm1 shows a homodimer “half transporter” in the inward 
conformation (Figure 1-25). It has a total of 6 TMD helices per half and is roughly 120Å x 85Å in 
size. Initial studies have shown that NaAtm1 shares ~45% sequence identity to the homologs 
ABCB7, HMT1, and yeast Atm1 [31]. Five different crystal structures for this protein have been 
reported (4MRN, 4MRP, 4MRR, 4MRV, 4MRS) with each crystal structure containing a different 
bound ligand (Apo, Reduced glutathione (GSH), Selenomethionine, S-Mercury glutathione, and 
Oxidized glutathione (GSSG) respectively) [31]. 







Figure 1-25. Dimension of NaAtm1 along with locations of the primary (red) and secondary (black) substrate binding 
sites as reported by Lee et al. [31]. 
 
1.10.2 NaAtm1 substrate binding sites 
Crystal structures have revealed two substrate binding sites (SBSs), with the main SBS 
located about 5Å into the transmembrane region. The second lower affinity site is located about 
5Å below the primary binding site. The primary binding site is formed by Asp316, Gly319, and 
Met320 from TMD6/TMD12 and Asn296 and Gln272 from TMD5/TMD11, while the secondary 
binding site is comprised of Arg206, 210 and 323.  
 
 
Figure 1-26. A) Primary binding site bound with the substrate S-Hg(GSH)2 B) Secondary binding site bound with the 




The relevance of these two sites is not yet fully understood; however, the relative 
orientation could accommodate a glutathione complexed iron-sulfur cluster ([2Fe:2S](GS-)4) 
(Figure 1-27) complex [31]. 
 
Figure 1-27. Structure of a glutathione complexed iron-sulfur cluster ([2Fe:2S](GS-)4). This may be a possible 
substrate that can interact with both binding pockets found within NaAtm1. 
 
1.10.3 In vitro characterization of NaAtm1 activity  
In addition to structural studies, preliminary kinetic assays revealed that NaAtm1 has a 
high affinity for the transition metals silver and mercury in complex with glutathione (Table 1-2). 
Substrates that do not include glutathione did not stimulate activity in this transporter, consistent 
with studies using homologs of NaAtm1 [78]. Interestingly, while it is accepted that GSH is a 
critical component involved in transport, reduced glutathione (GSH) stimulated relatively low 
transporter activity compared to oxidized glutathione (GSSG). This suggests that the natural 








Table 1-2. Kinetic constants for the ATPase activity of substrates in NaAtm1 as reported by Lee et al. [31] 
 
 To demonstrate that substrate was transported across a lipid bilayer, proteoliposomes 
containing reconstituted NaAtm1 was assayed. In the presence of wild-type NaAtm1 
proteoliposomes and ATP, increasing amounts of GSSG accumulated within the proteoliposomes 
as a function of time. These results indicated that the increased ATPase activity of NaAtm1 
correlated with transport of substrate across a lipid membrane. 
 
1.10.4 In vivo functionality of NaAtm1  
 To test if NaAtm1 exports the substrates silver and mercury in vivo, metal sensitive strains 
of E. coli were grown and subjected to metal salts (CuSO4, ZnSO4, CdCl2, AgNO3, and HgCl2). 
No protection was observed against Cu2+, Zn2+, or Cd2+, however protection was conferred by 
NaAtm1 for Ag2+ and Hg2+. These results suggest that Ag2+ and Hg2+ are capable of being exported 





1.11 Studies presented in this work 
 This thesis describes the development and optimization of an NaAtm1 lipid bilayer system 
designed for in vitro studies of transport. In Chapter 2, the general principles behind protein 
purification are described, followed by procedures and results for three different proteins. Chapter 
3 introduces the different lipid mimetic environments used in the study of ABC transporters. This 
chapter details the experiments and findings for the reconstitution of NaAtm1 into a lipid lipid-
filled structure referred to as a nanodisc. In Chapter 4, data from preliminary kinetic studies are 
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When studying protein function from a biochemical perspective, an essential first step is 
to isolate the protein of interest. The resulting protein must be reproducibly purified to a single 
species with high yield. During my time at USF I have developed and improved multiple protein 
purification methods for the purpose of purifying both single proteins (NaAtm1, MSP1D1, and 
TEV protease), as well as protein complexes (NaAtm1 reconstituted into nanodiscs). This chapter 
outlines the theories behind the primary techniques routinely employed during purification. 
Additionally, key specialized instruments for protein purification are described. Lastly, the 
methods used in the expression and purification of NaAtm1 and the accessory proteins MSP1D1 
and TEV protease are detailed. The purpose of the accessory proteins MSP1D1 and TEV protease 
will be described in Chapter 3. 
 
2.1 Method theories 
While the process of protein purification employs a myriad of materials and techniques, 
this section will focus on two chromatography-based techniques used for preparative purposes and 
one technique employed for analysis. The two chromatographic methods are immobilized metal 
affinity chromatography (IMAC) and size exclusion chromatography (SEC). Both types of 
chromatography are performed using an FPLC (Fast Protein Liquid Chromatography) instrument 
which is described later in this chapter. These chromatography methods are paired with an analysis 
method called sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) which is 





Chromatography: “A process in which a chemical mixture carried by a liquid or gas is separated 
into components as a result of differential distribution of the solutes as they 
flow around or over a stationary liquid or solid phase” [1]. 
 
2.1.1 Immobilized metal affinity chromatography (IMAC) 
 IMAC is a method of chromatography that uses a metal (typically nickel or copper) that 
has been immobilized to bind proteins of interest. IMAC was first developed by Porath et al. in 
1975 as a novel way to separate proteins [2]. Originally, iminodiacetic acid (IDA) was used as a 
metal immobilizer, however due to its weak binding of metals, a more effective immobilizer was 
developed by Hochui et al. in 1987 [3] (Figure 2-1). This new immobilizer – Nitrilotriacetic acid 
(NTA) – had the ability to bind to four of the six binding sites found in the coordination sphere of 
a nickel ion rather than the three sites bound by IDA [4]. Commercial IMAC columns use 










2.1.1.1 Poly-histidine tags  
To selectively interact with the nickel ion described above, proteins of interest are 
genetically modified to add a “His-tag”. His-tags were first described by Hochuli et al. in 1988 [5] 
and are comprised of 6-10 histidine residues that have been placed at either the N- or C-terminus 
of the protein of interest. For many proteins, protein folding and function are not significantly 
affected by the addition of a His-tag to one of the termini. Multiple histidine residues are introduced 
because the imidazole group on the side chain exhibits the highest affinity for metal ions of all the 
amino acids [6] (Figure 2-2). Purification using a His-tagged protein and Ni-NTA can increase 
target protein purity from less than 1% to up to more than 95% purity [4].  
 
 
Figure 2-2. A nickel-loaded Nitrilotriacetic acid (Ni-NTA) (blue) bound to resin (blue sphere) binding to part of a poly-
histidine tag (green) [7]. 
 
Once bound, the resin can be washed with the low concentrations of imidazole (10-50 mM) 
to remove any impurities, followed by elution from the column at higher concentrations (300-500 
mM). IMAC is routinely chosen as a primary purification method because it is robust, relatively 






2.1.2 Size exclusion chromatography (SEC) 
 Size exclusion chromatography is based on the use of a porous matrix to separate a 
mixture of particles by their molecular weight. In this porous matrix, smaller components of a 
mixture take longer to travel through the column than larger components. This is because the 
smaller components are able to fit into a larger percentage of pores and are temporarily impeded. 
This idea was first postulated by Synge and Tiselius [8] based on zeolite research by R. M. Barrer 
[9]. The first columns were packed with potato or maize starch, which have a very low adsorption 
of proteins [10]; however, they were not strong enough to withstand high linear velocities. Today, 
the most commonly used packing materials (referred to as size exclusion media) are small porous 
spheres made up of either cross-linked composite dextran, agarose, or polyacrylamide (Figure 2-
3) [11]. 
One way to understand this somewhat counter-intuitive technique is to imagine the size 
exclusion column and its resin as a large hollow cylinder filled with whiffle balls. If a mixture of golf 
balls and marbles were placed onto the top of this column, the marbles would be able to enter the 
whiffle balls while the golf balls could not – they would have to go around the whiffle balls. In this 
scenario the marbles have a longer path length through the column due to continually entering 
and exiting the interior of the whiffle balls. This results in the golf balls (the larger component of 
the mixture) to come out of the bottom of the cylinder first. Likewise, in size exclusion 
chromatography, the largest protein components are eluted first.  
One important feature of a SEC column is its void volume. The void volume of a column 
is the volume at which an unretained molecule elutes. To extend the analogy above, the golf balls, 
which do not get stuck in any whiffle balls, would elute at the void volume. Protein molecules 
eluting at the void volume are larger than what the column can resolve and are most commonly 






Figure 2-3. A) Sample of a size exclusion bead interacting with three different sized molecules. B) A size exclusion 
column at different times (column 1 = T0, 2 = T1, 3 = T2). The colors correspond to the different components 
of the mixture. C) A sample chromatogram showing the elution order of largest to smallest [12].  
 
 
While IMAC can yield a relatively pure sample enriched with the His-tagged protein, the 
elution may also contain aggregates and other impurities. Size exclusion chromatography can 
remove these impurities if the sizes are within the resolution ability of the resin. 
2.1.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Electrophoresis: “The movement of suspended particles through a medium (such as paper or 
gel) under the action of an electromotive force applied to electrodes in contact 
with the suspension” [13]. 
 
SDS-PAGE is a method of electrophoresis created by U.K. Laemmli in 1970 [14] that 




molecular mass by passing them through a polyacrylamide gel [15]. Polyacrylamide is used 
because it is chemically inert and produces different pore sizes at different concentrations.  
 
 
Figure 2-4. Components and composition of a typical SDS-PAGE experiment [16]. 
  
 
Proteins are first prepared for SDS-PAGE by denaturation using SDS, dithiothreitol (DTT) 
and heat. SDS denatures both the secondary and non-disulfide-linked tertiary structures, while 
DTT is a powerful reducing agent that breaks disulfide bonds [17]. Proteins must be denatured in 
order to ensure movement based on molecular mass and not on protein dimension. During this 
process, all proteins are turned into “rods” with a diameter of roughly one amino acid so that only 
their lengths determine how quickly they pass through the gel. In addition to denaturing the protein, 
SDS gives proteins a uniform net negative charge which is essential for unidirectional movement 
through the polyacrylamide gel. SDS binds amino acids with a general ratio of one SDS molecule 
to two amino acids. This “mass-to-charge” ratio is roughly the same for all molecules and allows 




The gel plate is comprised of polyacrylamide gel thinly sandwiched between glass or 
plastic plates. The gel is made up of two parts called the “stacking gel” and “running gel” (Figure 
2-4, right). The stacking gel is located at the upper portion of the gel and contains the sample wells. 
It is comprised of a lower concentration of polyacrylamide to produce a large pore size mixed with 
Tris-HCl buffer that has a lower pH (pH=6.8) than both the Tris-glycine running buffer (pH=8.3) 
and the running gel (pH=8.8) (Figure 2-4, left) This difference in pH is essential in producing a 
thin, uniform band of protein that is required for the running gel.  
When a charge is applied to the system, negatively charged glycine ions in the running 
buffer are forced into the stacking gel and encounter its lower pH environment. At pH=6.8, glycine 
is a zwitterionic molecule (neutrally charged) which results in very slow mobility through the 
stacking gel. The stacking gel also contains chloride ions (from the Tris-HCl) which are negatively 
charged and run much faster through the gel than the neutral glycine. As the chloride ions move 
towards the anode, an area of positive counter ions is created which results in a large voltage 
gradient between the chloride ions and glycine. All of the proteins are within this gradient and are 
“stacked” based on their electrophoretic mobility into thin layers at the boundary between the 
stacking gel and running gel [18]. 
The running gel starts at the bottom of the stacking gel and continues to the bottom of the 
gel plate. It contains a higher concentration of polyacrylamide to produce a smaller pore size and 
has a higher pH than that of the stacking gel. Upon reaching the running gel, the stacked protein 
sample encounters the dramatic change in pore size and pH. The increase in pH (to pH=8.8) results 
in glycine returning to a negative charge and moving much faster, leaving the sample protein to 
make its way through the gel alone. The smaller pore size causes the proteins in the sample to 





Figure 2-5. Mechanics of the stacking gel and loading gel. The stacking gel (A) is located above the running gel and 
has a pH of 6.8. At this pH, glycine molecules contain no net charge and move much more slowly than the 
chloride ions, creating a voltage gradient. Proteins (red lines) in this gel are pulled along behind the fast 
moving chloride ions and “stacked” at the boundary between the stacking gel and running gel. The running 
gel has a pH of 8.8 which causes the glycine to have a negative charge and results in both glycine and the 
chloride ions leaving the protein to move on its own. In this gel, the speed of the protein is inversely related 
to its size, with small proteins moving faster than large proteins [18]. 
 
 
Ultimately, SDS-PAGE separates the different proteins within a sample by molecular 
weight, and in combination with various staining methods, allows for detection of these molecules 
(Figure 2-6). This technique is commonly used to assess the results of each step in a purification 
process.  SDS-PAGE analysis can identify the enrichment or loss of a target protein, allowing for 
optimization and troubleshooting of the method. Finally, the purity and yield of a final protein 






Figure 2-6. SDS-PAGE gel comprised of different samples taken during the purification of 
NaAtm1. Samples are more fully described in Section 2.3.6. 
 
2.2 Specialized instruments 
 This section will focus on two specialized instruments used during the purification process: 







2.2.1 Fast Protein Liquid Chromatography (FPLC) instrument 
The FPLC instrument is essential 
for purifying proteins. The AKTA Pure 
(GE Healthcare) employed in this study 
has several features including two 
independent pumps, a column valve, an 
injector port, and a fractionator for 
collecting samples. It records system 
pressure, pre-column pressure, delta 
column pressure, absorbance at 280 nm, 
and conductivity. The specific commercially available columns used in this work are as follows:  
 
1. Ni-NTA HisTrap column: 
HisTrap columns contain Ni-NTA resin (as described in the IMAC section above) and are 
used to purify His-tagged proteins. The columns utilized here were either 1 mL or 5 mL in 
volume, with a reported capacity of approximately 40 mg His-tagged per mL of resin.  
 
2. HiPrep 26/10 Desalting: 
This column is used for group separation of proteins from much smaller molecules. It is 
most commonly used for buffer exchange after a particular chromatographic step. The 
“HiPrep” name reflects the nature of its use; the maximum sample volume of 10 mL allows 
for buffer exchange of larger scale protein preparations.  
 







This size exclusion column is ideal for protein separation in the 10,000 - 600,000 Da range. 
It has the ability to handle up to 5mL of sample per run and is commonly used as a 
secondary purification method in large scale preparations, employed to remove 
contaminants of significantly differing size from that of the protein of interest. 
 
4.  Superdex 200 Increase 10/300 GL: 
This size exclusion column is ideal for protein separation in the 10,000 - 600,000 Da range 
however its maximum sample volume is much smaller, only 0.5 mL and thus is used for 
smaller scale preparations. 
  
2.2.2 Spectrophotometer 
 A microvolume spectrophotometer was 
used to determine the concentrations of all purified 
proteins by measuring the proteins absorbance at 
280 nm. An accurate concentration can be obtained 
by using the proteins extinction coefficient (a 
number derived using the total amount of amino 
acids that absorb at 280 nm found within the target 
protein). The nanophotometer is used because It can accurately measure absorption using 2uL of 
protein, allowing for the conservation of the small amount of final purified protein that is produced 
during one purification run (around 1 mL total). 
 
 





2.3 Purification of NaAtm1 
 2.3.1 NaAtm1 purification overview 
To isolate the ABC exporter NaAtm1 for 
biochemical studies, an over-expression and 
purification method was employed based on a 
previously published procedure [23]. This 
protocol was modified as detailed below to yield 
higher purity and increased yield. Using this 
optimized protocol, ~10 mg of purified NaAtm1 
per 30 g of cells was routinely obtained.  
 
2.3.2 NaAtm1 protein expression 
 The DNA plasmid containing full-length NaAtm1 was a gift of Douglas Rees (California 
Institute of Technology). The gene was encoded in a pJL-H6 ligation-independent cloning vector, 
which added a 6x histidine tag on the carboxy terminus of the protein. The plasmid was 
transformed into BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures. 
Transformed E. coli were selected for on agar plates containing 100 µg/mL ampicillin. Single 
colonies were then used to inoculate 5 mL of LB media containing 100 µg/mL ampicillin. Cultures 
were incubated at 37 °C while shaking at 225 rpm for six hours. After six hours, each culture was 
transferred to a Fernbach flask containing 900 mL of ZYM-5052 auto-induction media (1% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 0.4% (v/v) glycerol, 0.2% (w/v) lactose, and 0.05% (w/v) 
dextrose), 100 mL of 10x phosphate buffer (0.17 M KH2PO4, 0.72 M K2HPO4), and 100 µg/mL 
ampicillin. Four Fernbach flasks were incubated at 37 °C while being shaken at 180 rpm overnight. 
The next morning the cell cultures were centrifuged at 18,370 xg for 20 minutes to pellet the cells. 




Approximately 30 g of cells were routinely obtained from 4 L of culture.  Harvested cells were 
either immediately used in the purification process or flash frozen using liquid nitrogen and stored 
at -80 °C until needed.  
 
2.3.3 NaAtm1 protein purification 
 NaAtm1 was purified using an ÄTKA Pure FPLC System (GE Healthcare) via 
immobilized metal affinity chromatography followed by size exclusion chromatography. All 
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. 30 g of cells were 
homogenized in 300 mL of NaAtm1 buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.05% 
n-Dodecyl β-D-maltoside (DDM, Anatrace)). 10 mg Deoxyribonuclease I (Sigma), 10 mg 
lysozyme (Sigma), 1.5 mL of 200 mM PMSF, and 3 g of DDM (1% w/v) were added to the cells 
and was stirred for 20 minutes. The suspension was sonicated on ice using a flat tip sonicator with 
20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling for 7 cycles for a total of 
5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg for 20 minutes. The 
clarified supernatant was collected and 4 M imidazole (pH 8) was added to a final concentration 
of 25 mM. The lysate was then injected onto a 5 mL Ni-NTA HisTrap HP column (GE Healthcare) 
and washed with 75 mL of NaAtm1 buffer containing 35 mM imidazole. The column was eluted 
with 20 mL of NaAtm1 buffer containing a final concentration of 350 mM imidazole. Peak 
fractions were collected and loaded onto a HiPrep 26/10 Desalting column (GE Healthcare) 
equilibrated in NaAtm1 buffer to remove imidazole. Peak fractions were collected, pooled 
(typically 10-12 mL total) and frozen in liquid nitrogen and stored at -80 ˚C. The next day, the 
eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon Ultra-
15 centricon with a 100,000 kD molecular weight cutoff (Millipore) and injected onto a Superdex 




elution volume) were collected, pooled, and concentrated as before until the final protein 
concentration was approximately 15 mg/mL (extinction coefficient 152,640 M-1cm-1). Final 
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed. 
 
2.3.4 NaAtm1 IMAC purification results 
Immobilized metal affinity chromatography purification was carried out using both the 
High Performance (HP) and Fast Flow (FF) versions of the 5 mL HisTrap (Ni-NTA) columns 
produced by GE Healthcare. Results from these purifications showed that the HP HisTrap was 
able to capture roughly twice the amount of NaAtm1 as the FF HisTrap (Figure 2-10). NaAtm1 
purification consisted of four phases: loading, washing, eluting and desalting. During this 
purification process, imidazole is used to prevent non-specific binding during loading, remove 
contaminants during washing, and elute the target protein during elution.  During the loading 
phase, 4 M imidazole was added to roughly 300 mL of clarified supernatant containing NaAtm1, 
bringing the total imidazole concentration to 25 mM. The supernatant was flowed over a HisTrap 
column. This phase always produced a steady UV reading of around 2300 mAU, representing the 
abundance of proteins in the cellular lysate. Once the loading phase was complete, a washing phase 
using 35 mM imidazole and lasting 15 column volumes (CV) took place. This phase resulted in a 
rapid decline in the UV reading from ~2300 mAU down to roughly 20 mAU. This decrease 
indicates that the vast majority of non-specific-bound protein had been removed from the column 
and suggests that only NaAtm1 is left bound to the column. Once washed, the protein was removed 
from the column during the elution phase using 350 mM imidazole. This phase produced a sharp 
peak of between 600 mAU and 2000 mAU followed by a steady UV reading of about 100 mAU 





Figure 2-10. Comparison of the elution peaks for WT NaAtm1 using 5 mL HisTrap FF (blue) and 5 mL HisTrap HP 
(orange) Ni-NTA columns. The HisTrap HP consistently produced elution peaks more than twice as large 
as the HisTrap FF given the same amount of starting material.  
 
 
The elution peak was immediately flowed over a HiPrep 26/10 Desalting column to 
separate NaAtm1 from the imidazole used to elute the protein from the HisTrap column. Imidazole 
needs to be removed immediately as it can interfere with enzyme activity and may destabilize the 
protein. This process always produced a bell-curve shape starting around 10 mL and ending around 


































Figure 2-11. Imidazole separation from NaAtm1 using a Size exclusion “Desalting” column. This 
chromatogram shows only the peak of NaAtm1. 
 
 
2.3.5 NaAtm1 SEC purification results 
 Following elution from the desalting column, a secondary purification process using size 
exclusion chromatography was performed. This process uses a 120 mL HiLoad 16/600 Superdex 
200 pg size exclusion column to remove both impurities and aggregates of NaAtm1. 
Chromatograms for this process usually display two peaks at 50 mL and 64 mL (Figure 2-12). The 
50 mL peak, representing the void volume of the column, contained aggregated NaAtm1 (data not 


































Figure 2-12. Size exclusion chromatogram of secondary purification of wild-type NaAtm1. 
 
 
2.3.6 Analysis of NaAtm1 
 Samples were collected throughout the purification process and analyzed using SDS-
PAGE. As seen in samples of the lysate, pellet, and supernatant, NaAtm1 was successfully 
overexpressed in cells (Figure 2-13, red arrow); however, as NaAtm1 is a membrane protein, the 
majority of expressed protein remained in the pellet, despite the presence of high concentrations 
of detergent (Figure 2-13, green arrow). The decrease of the NaAtm1 in the flow through indicated 
that majority of NaAtm1 selectively bound to the Ni-NTA resin, and the wash sample contained 
mostly non-specific proteins. While the eluate for Ni-NTA and desalt columns contained multiple 
proteins, the NaAtm1 band was considerably enriched relative to all other bands. Finally, the 









































1 Ladder Molecular weight ladder (Bio-rad)
2 Lysate Cellular lysate post-sonification.
3 Pellet Insoluble cellular components, taken immediately after centrifugation 
of cell lysate.
4 Supernatant Soluble proteins, taken immediately after centrifugation of cell lysate.
5 Flow Through Proteins that did not bind to HisTrap column 
6 Wash Low imidazole wash of His-Trap column
7 Fractions Pooled peak fractions from high imidazole elution 
8 Desalt Pooled peak fractions from desalting column
9 Final (1 µL) 1 µL of the pooled and concentrated fractions from size exclusion 
column 





2.4 Purification of MSP1D1 
 MSP1D1 is an accessory protein 
used in the assembly of nanodiscs, a 
lipidic environment developed for the 
study of integral membrane proteins 
(Figure 2-14, orange and yellow). A full 
description of its history, structure, and 
implementation can be found in Chapter 
3: Creating a Realistic Environment In 
Vitro. 
         
2.4.1 MSP1D1 purification overview 
The Sligar Group at the University of Illinois Urbana Champaign originally cloned 
MSP1D1 and developed methods for over-expression and purification.  This protocol, however, is 
extremely reagent and labor intensive (requiring seven different buffers), and thus an alternative 
method was developed, as described here.  This new MSP1D1 purification strategy was based on 
NaAtm1, and showed similar yield and purity as the Sligar method. Using this more efficient and 
streamlined protocol, ~50 mg of purified MSP1D1 per 15 g of cells was routinely obtained.  
  
2.4.2 MSP1D1 protein expression 
         The DNA plasmid containing full-length MSP1D1 was a gift of Douglas Rees (California 
Institute of Technology). The gene was encoded in a pJL-H6 ligation-independent cloning vector 
which added a 6x histidine tag on the carboxy-terminus of the protein. The plasmid was 
transformed into BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures. 
 
Figure 2-14. Structure of an empty Nano-disc 
containing two MSP1D1 proteins 
(yellow and orange) surrounding a lipid 




Transformed E. coli were selected for on agar plates containing 50 µg/mL kanamycin. Single 
colonies were then used to inoculate 5 mL of LB media containing 50 µg/mL kanamycin. Cultures 
were incubated at 37 °C while shaking at 225 rpm overnight. The next morning, each culture was 
transferred to a fernbach flask containing 900 mL of Terrific Broth (TB) media (2.0% (w/v) 
tryptone, 2.4% (w/v) yeast extract, and 0.4% (v/v) glycerol), 100 mL of 10x phosphate buffer 
(0.017 M KH2PO4, 0.072 M K2HPO4), and 50 µg/mL kanamycin. Four Fernbach flasks were 
incubated at 37 °C while being shaken at 180 rpm until the optical density of all flasks were ~0.5. 
Once all flasks reached ~0.5 OD, the lactose analog IPTG was added to a final concentration of 1 
mM to induce protein overexpression. The cultures were grown for an additional three hours 
before being harvested via centrifugation at 18,370 xg for 20 minutes. Approximately 15 g of cells 
were routinely obtained from 4 L of culture.  Harvested cells were either immediately used in the 
purification process or flash frozen using liquid nitrogen and stored at -80 °C until needed. 
 
2.4.3 MSP1D1 protein purification 
         MSP1D1 was purified using an ÄTKA Pure FPLC System (GE Healthcare) via 
immobilized metal affinity chromatography followed by size exclusion chromatography. All 
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. ~15 g of cells 
were homogenized in 150 mL of MSP1D1 buffer (40 mM Tris-HCl, pH 7.5 and 300 mM NaCl). 
10 mg Deoxyribonuclease I (Sigma), 10 mg lysozyme (Sigma), and 1.5 mL of 200 mM PMSF 
were added to the cells and was stirred for 10 minutes. The suspension was sonicated on ice using 
a flat tip sonicator with 20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling 
for 7 cycles for a total of 5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg 
for 20 minutes. The clarified supernatant was collected and 4 M imidazole (pH 8) was added to a 




column (GE Healthcare) and washed with 75 mL of MSP1D1 buffer containing 35 mM imidazole. 
The column was eluted with 20 mL of MSP1D1 buffer containing a final concentration of 350 mM 
imidazole. Peak fractions were collected and loaded onto a HiPrep 26/10 Desalting column (GE 
Healthcare) equilibrated in MSP1D1 buffer to remove imidazole. Peak fractions were collected, 
pooled (typically 10-12 mL total) and frozen in liquid nitrogen and stored at -80 ˚C. The next day, 
the eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon 
Ultra-15 centricon with a 10,000 kD molecular weight cutoff (Millipore) and injected onto a 
Superdex 200 pg 16/600 sizing column (GE Healthcare). Peak fractions (eluting at approximately 
75 mL elution volume) were collected, pooled, and concentrated as before until the final protein 
concentration was approximately 15 mg/mL (extinction coefficient 21,430 M-1cm-1). Final 
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed. 
 
2.4.4 MSP1D1 IMAC purification results 
Immobilized metal affinity chromatography purification was carried out using a High 
Performance (HP) 5 mL HisTrap (Ni-NTA) columns produced by GE Healthcare. MSP1D1 
purification consisted of four phases: loading, washing, eluting and desalting. The resulting 
profiles are similar to those seen in the NaAtm1 purification procedure. During the loading phase, 
roughly 150 mL of clarified supernatant containing overexpressed MSP1D1 was flowed over a 
HisTrap column. This phase always produced a steady UV reading of around 2600 mAU, 
representing the abundance of proteins in the cellular lysate. Once the loading phase was complete, 
a washing phase lasting 15 column volumes (CV) took place. This phase resulted in a rapid decline 
in the UV reading from ~2600 mAU down to roughly 20 mAU. This step was necessary to remove 
any non-specific proteins bound to the column. Once washed, the protein was removed from the 




UV reading of about 100 mAU due to the high imidazole concentration (Figure 2-15). The height 
of the absorbance peak indicated a high concentration of protein was present in the eluate. 
 
Figure 2-15. Primary purification of MSP1D1 using a 5 mL HisTrap HP column. 
 
Once eluted, the peak fractions were immediately flowed over a HiPrep 26/10 Desalting 
column to separate MSP1D1 from the high concentration of imidazole used in Ni-NTA elution. 































Figure 2-16. Imidazole separation from MSP1D1 using a size exclusion-type “desalting” column.  
 
 
2.4.5 MSP1D1 SEC purification results 
 Following elution from the desalting column, a secondary purification process using size 
exclusion chromatography was performed. This process employed a 120 mL HiLoad 16/600 
Superdex 200 pg size exclusion column to remove any remaining impurities and aggregates of 
MSP1D1. Chromatograms for this process routinely displayed two peaks at 50 mL and 75 mL 
(Figure 2-17). The protein eluting at the 50 mL void volume was comprised of aggregated 
MSP1D1 (data not shown), while the peak at 75 ml consisted of purified MSP1D1. A faint shoulder 
was normally seen after the main peak eluted. These fractions were not collected and not part of 

































Figure 2-17. Size exclusion chromatogram of secondary purification of MSP1D1 
 
 
2.4.6 Analysis of MSP1D1 
 Samples were collected throughout the purification process and analyzed using SDS-
PAGE. The purification of MSP1D1 can be followed using these samples (Figure 2-18, red arrow). 
The absence of the MSP1D1 in the flow through indicated that MSP1D1 selectively bound to the 
Ni-NTA resin, and the wash sample contained only non-specific proteins. While the eluate for Ni-
NTA and desalt columns contained multiple proteins, the MSP1D1 band was considerably 
enriched relative to all other bands. Finally, the elution sample taken following SEC showed the 



































1 Ladder Molecular weight ladder (Bio-rad)
2 Lysate Cellular lysate post-sonification.
3 Pellet Insoluble cellular components, taken immediately after 
centrifugation of cell lysate.
4 Supernatant Soluble proteins, taken immediately after centrifugation of cell 
lysate.
5 Flow Through Proteins that did not bind to HisTrap column 
6 Wash Low imidazole wash of His-Trap column
7 Fractions Pooled peak fractions from high imidazole elution 
8 Desalt Pooled peak fractions from desalting column
9 Final (1 µL) 1 µL of the pooled and concentrated fractions from size exclusion 
column 
10 Final (1 µg) 1 µg of the pooled and concentrated fractions from size exclusion 
column  
 






2.5 Purification of TEV protease 
TEV Protease is a highly specific protease that 
is used to remove engineered His-tags from proteins 
produced in a heterologous expression system. This 
protein and its application are described in detail in 
Chapter 3: Creating a Realistic Environment in Vitro.  
 
2.5.1 TEV protease purification overview 
The TEV protease purification strategy follows a procedure developed by the Narlikar 
Group at the University of California, San Francisco.  Using a modified version of this protocol, 
~10 mg of purified TEV protease per 15 g of cells was obtained. 
 
2.5.2 TEV protease protein expression        
The DNA plasmid containing full-length S219V mutant TEV protease was a gift from 
Geeta Narlikar. The gene was encoded in a pMal-C2 ligation-independent cloning vector which 
added a 6x histidine tag on the carboxy terminus of the protein. The plasmid was transformed into 
BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures. Transformed E. coli 
were selected for on agar plates containing 100 µg/mL ampicillin. Single colonies were then used 
to inoculate 5 mL of LB media containing 100 µg/mL ampicillin. Cultures were incubated at 37 
°C while shaking at 225 rpm overnight. The next morning, each culture was transferred to a 
Fernbach flask containing 1 L of 2x Luria Broth (LB) media (2% (w/v) tryptone, 1% (w/v) yeast 
extract, and 2% (v/v) NaCl) and 100 µg/mL ampicillin. Four Fernbach flasks were incubated at 37 
°C while being shaken at 180 rpm until the optical density of all flasks were ~0.5. Once all flasks 
 
 
Figure 2-19. Cartoon model of 




reached ~0.5 OD, the lactose analog IPTG was added to a final concentration of 0.4 mM to induce 
protein production. The flasks were then incubated at 18 °C while shaking at 180 rpm overnight. 
The next morning, the cell cultures were centrifuged at 18,730 xg for 20 minutes to pellet the cells. 
Approximately 15 g of cells were obtained from 4 L of culture.  Harvested cells were either 
immediately used in the purification process or flash frozen using liquid nitrogen and stored at -
80 °C until needed. 
 
2.5.3 TEV protease protein purification 
         TEV protease was purified using an ÄTKA Pure FPLC System (GE Healthcare) via 
immobilized metal affinity chromatography followed by size exclusion chromatography. All 
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. ~15 g of cells 
were homogenized in 150 mL of TEV protease lysis buffer (1x PBS, 300 mM KCl, 10% glycerol, 
and 7.5 mM Imidazole pH 7.5). 10 mg Deoxyribonuclease I (Sigma) and 10 mg lysozyme (Sigma) 
were added to the cells and was stirred for 10 minutes. The suspension was sonicated on ice using 
a flat tip sonicator with 20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling 
for 7 cycles for a total of 5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg 
for 20 minutes. The clarified supernatant was collected and 4 M imidazole (pH 8) was added to a 
final concentration of 20 mM. The lysate was then injected onto a 5 mL Ni-NTA HisTrap HP 
column (GE Healthcare) and washed with 75 mL of TEV protease lysis buffer containing 35 mM 
imidazole. The column was eluted with 20 mL of TEV protease elution buffer (25 mM HEPES, 
100 mM KCl, 10% glycerol, and 500 mM Imidazole pH 7.5) containing a final concentration of 
350 mM imidazole. Peak fractions were collected and loaded onto a HiPrep 26/10 Desalting 




KCl, 10% glycerol, and 2 mM DTT pH 7.5) to remove imidazole. Peak fractions were collected, 
pooled (typically 10-12 mL total), frozen in liquid nitrogen and stored at -80 ˚C. The next day, the 
eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon Ultra-
15 centricon with a 10,000 kD molecular weight cutoff (Millipore) and injected onto a Superdex 
200 pg 16/600 sizing column (GE Healthcare). Peak fractions (eluting at approximately 75 mL 
elution volume) were collected, pooled, and concentrated as before until the final protein 
concentration was approximately 15 mg/mL (extinction coefficient 36,130 M-1cm-1). Final 
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed. 
 
2.5.4 TEV protease IMAC purification results 
Immobilized metal affinity chromatography purification was carried out using a High 
Performance (HP) 5 mL HisTrap (Ni-NTA) columns produced by GE Healthcare. TEV protease 
purification consisted of four phases: loading, washing, eluting and desalting. During the loading 
phase, roughly 150 mL of clarified supernatant containing TEV protease was flowed over a 
HisTrap column. This phase produced a steady UV reading of around 2500 mAU. Once the loading 
phase was complete, a washing phase lasting 15 column volumes (CV) took place. This phase 
resulted in a rapid decline in the UV reading down to roughly 20 mAU. After washing, the TEV 
protein was removed from the column during the elution phase. This phase produced a broad peak 





Figure 2-20. Primary purification of TEV using a 5 mL HisTrap HP column. 
  
Once eluted, the fractions containing the elution peak were immediately flowed over a 
HiPrep 26/10Desalting column to remove imidazole from the TEV protease This process always 
produced a bell-curve shape starting around 10 mL and ending around 25 mL (Figure 2-21). 
 























































2.5.5 TEV protease SEC purification results 
 Following elution from the desalting column, a secondary purification process using size 
exclusion chromatography was performed. This process uses a 120 mL HiLoad 16/600 Superdex 
200 pg size exclusion column to remove both impurities and aggregates of TEV protease. The 
chromatogram for this process displayed multiple peaks with the largest eluting at 90 mL (Figure 
2-22). For this purification, only the largest peak was evaluated; no analysis was done on the 
smaller peaks.   
 
Figure 2-22. Size exclusion chromatogram of secondary purification of TEV protease. 
 
2.5.6 Analysis of TEV Protease 
 Samples were collected throughout the purification process and analyzed using SDS-
PAGE. As seen in samples of the lysate, pellet, and supernatant, TEV protease was successfully 
overexpressed in cells (Figure 2-23, red arrow). The absence of the TEV protease in the flow 
through indicated that TEV protease selectively bound to the Ni-NTA resin, and the wash sample 
contained only non-specific proteins. While the eluate for Ni-NTA and desalt columns contained 




































1 Ladder Molecular weight ladder (Bio-rad)
2 Lysate Cellular lysate post-sonification.
3 Pellet Insoluble cellular components, taken immediately after centrifugation 
of cell lysate.
4 Supernatant Soluble proteins, taken immediately after centrifugation of cell lysate. 
5 Flow Through Proteins that did not bind to HisTrap column 
6 Wash Low imidazole wash of His-Trap column
7 Fractions Pooled peak fractions from high imidazole elution 
8 Desalt Pooled peak fractions from desalting column
9 Final (1 µL) 1 µL of the pooled and concentrated fractions from size exclusion 
column  
10 Final (1 µg) 1 µg of the pooled and concentrated fractions from size exclusion 
column  
 






 This chapter highlights some of the indispensable tools used in protein purification, which 
is the essential first step in most biochemical studies. Immobilized metal affinity chromatography 
(IMAC) and size exclusion chromatography (SEC), in combination with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), were used in the purification of three different 
proteins overexpressed in E.coli: NaAtm1, MSP1D1, and TEV protease. Using experimental 
conditions optimized for each protein, all three were successfully obtained with high purity and 
yield. With these components in-hand, the next step was to utilize MSP1D1 and TEV protease to 
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Creating a Realistic Environment in Vitro 
 
3.1 Introduction 
 In order to accurately dissect the mechanism of any protein of interest, experiments must 
be performed under conditions that mimic the native environment as closely as possible. In order 
to understand how NaAtm1 drives transport in a membrane, we aimed to incorporate NaAtm1 into 
a robust and reliable lipid bilayer system.  
I have always thought of ABC transporters as the doorways of the cell. Indeed, they are 
devices that allow selective passage through a lipid bilayer (wall), they have mechanisms (NBDs) 
that require energy to physically change their 3D structure (door handles), and they have conserved 
amino acid sequences that allow these conformational changes to take place (hinges). 
Unfortunately, as with most doors, when they are removed from their wall they no longer act as 
doors. If one wanted to study how these doors opened and closed, it would be advantageous to 
make a temporary frame, wall, or room to put them in. There are three common environments used 





Figure 3-1. Analogies to the different environments created for membrane protein experiments A) A bare membrane 
protein: without a supporting structure the protein will not function – like a door without a frame. B) A 
membrane protein surrounded by a detergent micelle: a minimum supporting structure that allows the 
protein to function – like a flimsy door frame around a door. C) A protein surrounded by a liposome: a full 
replica of a cell – like building an entire room for a door (more effort than necessary). D) A membrane 
protein surrounded by a nanodisc: acts as a wall that can give the door proper structure to function while 




3.2 Types of Environments 
 To maintain its inclusion within a lipid bilayer, integral membrane proteins, including ABC 
transporters, have many hydrophobic residues lining the exterior surface of the transmembrane 
domains. If a transporter is removed from the lipid bilayer and placed into an aqueous environment, 
these hydrophobic residues will rearrange to fold in on themselves or will drive the aggregation of 
multiple protein molecules. To maintain the structure of transporters after extraction from the 







3.2.1 Detergent micelles 
A detergent micelle is a self-assembling collection of surfactants – 
amphipathic molecules that contain a hydrophilic polar head group and a 
hydrophobic non-polar tail. When a critical concentration of these 
molecules is reached, they assemble in an organized way that creates a 
sphere of polar head groups with the non-polar tails on the interior of this sphere (Figure 3-2).  
If present above the critical micelle concentration, detergents can cover the hydrophobic 
portions of a transporter to prevent deformation and aggregation. While this alleviates some of the 
issues involved with isolating a membrane protein in aqueous solution, it does have limitations. 
The architecture of the surrounding micelle is fundamentally different from a bilayer, introducing 
artificial contacts between the hydrophobic surfaces of the protein and its environment. These 
interactions could alter native structure and dynamics of the transporter and therefore change its 
activity.  
Additionally, the micelle environment does not allow for the ability to directly monitor the 
movement of substrate across a membrane. Given the lack of a discrete compartment in which 
substrate can accumulate, experiments to measure transporter activity are limited to indirect 









Figure 3-2. Structure 




3.2.2  Liposomes 
Liposomes are artificially created vesicles – spheres composed of 
a closed phospholipid bilayer (Figure 3-3). Phospholipids are similar to 
detergents in that they have a polar head and a hydrophobic tail 
component, however their chemical structure is very different. One major 
difference is that detergents only have one hydrophobic tail while 
phospholipids have two (Figure 3-4). The ultimate effect of the two lipid tails is the formation of 
a lipid bilayer, and if there is enough bilayer, it is thermodynamically favored to close upon itself 
when in aqueous solution. There are both advantages and disadvantages to using liposomes over 
micelles. One major advantage is that liposomes have a true phospholipid bilayer that more closely 
resembles the natural membrane environment. Another advantage is that due to the closed nature 
of the environment (presence of the internal cavity), transporters that are placed in a liposome can 
be evaluated for substrate transport.  
 
Figure 3-4. Structures of the phospholipid phosphatidylcholine (PC) and the detergent sodium dodecyl sulfate (SDS). 
 
 
Figure 3-3. Structure 





Figure 3-5. Liposome containing a 1:1 ratio of inward and outward facing ABC transporters. In this scenario the ABC 
transporters are importers. 
 
 
Unfortunately, creating and maintaining liposomes can be very challenging due to their 
size. A major experimental challenge in using ABC transporters in a liposome is its orientation 
within the membrane. While many scientists assume an equal distribution (50% outward, 50% 
inward, Figure 3-5), the specific activity of the transporter is difficult to accurately measure. 
Furthermore, the insertion of membrane proteins into a liposome is demanding in practice – large 
amounts of protein must be available for reconstitution procedures which may require multiple 
rounds of optimization given a particular transporter.  
 
3.2.3  Nanodiscs 
Nanodiscs are small sections of phospholipid bilayer held together by an alpha-helical 
protein belt. This belt is a genetically modified form of human apolipoprotein A1 (Figure 32a). 
Apolipoprotein A1 is a major protein component of HDL particles found in plasma and plays a 
major role in lipid transport throughout the body [2]. It is comprised of a globular region followed 




in 1998 [3], with the modified apolipoprotein described as a “Membrane Scaffold Protein” (MSP). 
All MSPs have been modified by replacing the globular region with a histidine tag and TEV 
protease cleavage site, and each contain varying numbers of α-helices.  By varying the number of 
α-helices contained in the MSP, the final disc diameter can be modulated to accommodate different 
sizes of transmembrane proteins. Membrane scaffold proteins are now widely available in 
diameters ranging from 7 to 17 nm. 
 
 
Figure 3-6. A) Structure of a nanodisc containing a transmembrane protein (green), surrounded by a phospholipid 
bilayer (red spheres with gray tails), held together by two modified Apolipoproteins (MSPs) (purple). B) 
Organization of the naturally occurring Apolipoprotein A1 and two genetically modified MSPs, MSP1D1 
and MSP1E3D1 [4]. 
 
 
In contrast to liposomes, nanodiscs are relatively easy to generate in a self-assembling 
process. As with the detergent micelle, this system is open, which makes it impossible to determine 
if a substrate is being transported through the protein or if it is merely stimulating activity. Even 
with this drawback, they are less labor intensive and more durable than liposomes while creating 
a more realistic environment than detergent micelles. While detergent micelles stabilize isolated 
membrane proteins in an aqueous solution and are relatively easy to create, there have been 
discrepancies in enzyme activity based on the choice of mimetic environment in general. For 
example, BtuCD transporters reconstituted into nanodiscs have been shown to have an almost 6-




believed that these discrepancies come from the detergents causing the protein to adopt a structure 
that is different from the one it takes in lipid. To address this issue and to create a more realistic 
environment to test NaAtm1, we aimed to insert NaAtm1 into nanodiscs as described below. 
 
3.3 Overview of nanodisc reconstitutions 
 NaAtm1 nanodiscs are created in a self-assembling reaction that requires purified 
Membrane Scaffold Protein (MSP), micelles containing a mixture of lipid and detergent, and 
purified NaAtm1 in detergent micelles. When these components are mixed using an optimized 
molar ratio of NaAtm1-MSP1D1-Lipid, small polystyrene “Bio-Beads” are added. These beads 
absorb the detergent from both the purified NaAtm1 as well as the lipid/detergent micelles while 
leaving the lipid component untouched. This results in the accumulation of lipid around NaAtm1 
and other lipids.  The MSP1D1 then wraps around the lipid to form both full discs (containing 
embedded transporter) and empty discs (Figure 3-7). Finally, the full disc species is isolated via 
chromatography.  
 
Figure 3-7. Overview of the nanodisc reconstitution process [6, 7]. This process consists of combining the target 
membrane protein with MSP, lipid/detergent micelles, and Bio-Beads. The Bio-Beads absorb the detergent 
from the lipid/detergent micelles as well as the detergent micelles around the target membrane protein. 
This process results in the accumulation of lipid around the membrane protein and other lipids resulting in 




3.3.1.  Preparation of nanodisc reagents 
3.3.1.1 Membrane scaffold protein (MSP) 
 
The NaAtm1 reconstitutions described here employs MSP1D1, 
which was chosen due to its availability and final diameter of ~9.7 nm. 
At ~9.7 nm, the lipidic area accommodates only one NaAtm1. MSP1D1 
contains an N-terminal His-tag (7x histidine residues), a TEV protease 
cleavage site, and ten α-helices (Figure 3-9B). Two MSP1D1 proteins 
wrap around the lipid bilayer form one disc that measures roughly 9.8 nm in diameter and 4.6 nm 
(lipid bilayer only) in height. The purification of this protein can be found in Chapter 2.  
 
Figure 3-9. A) The amino acid sequence of MSP1D1. B) Comparison of Apolipoprotein A1 and MSP1D1 [4]. 
 
3.3.1.2 1:3 PC:E lipids 
 The lipid mixture used in reconstitutions was based on previous studies using ABC 
transporters [8]. A 1:3 ratio of chicken egg phosphatidylcholine (PC) to E. coli polar lipid extract 
is a common starting point for reconstitutions. The composition of each of these components is 
shown in Figure 3-10.  
 
Figure 3-8: Cartoon 






Figure 3-10. A) Natural lipid mixture found in chicken egg PC. B) Composition of E. coli polar extract. C) Representative 
structure of phosphatidylcholine (PC) from chicken egg [9, 10]. 
 
To prepare this lipid mixture, commercially available chloroform stocks of egg PC and E. 
coli polar lipid extract were mixed with a final mass of 100 mg of chicken egg PC to 300 mg of E. 
coli polar extract (Avanti Polar Lipids). Lipids were transferred to a 500  mL balloon flask and 
rotovaped to remove chloroform. Once dry, the flask was wrapped in tinfoil to prevent 
photodegredation, and was placed in a desiccator overnight under vacuum to remove any 
remaining chloroform.  
 The next morning, 15 mL of Reconstitution Buffer A (20 mM Tris HCl (pH 7.5) and 100 
mM NaCl) was added to the flask. The mixture was then placed under argon to prevent oxidation 
and shaken overnight at room temperature at 120 rpm. The following day, the resuspended lipids 
were collected, and 5 mL of Reconstitution Buffer A was added to the flask to recover any 
remaining lipid. The resuspended lipids were then brought to a final concentration of 20 mg/mL 
in Reconstitution Buffer A. This lipid stock was then placed on ice and sonicated using a using a 




sonification with a 45 second cool-down period in between. Once sonicated, the lipids were 
divided into 100 µL aliquots, flash frozen in liquid nitrogen, and stored at -80 °C.  
 For use in reconstitutions, lipids were further processed on a smaller scale. Because 
nanodiscs form upon removal of detergent, both from the hydrophobic region of the membrane 
protein and from the lipid/detergent micelles by Bio-beads, the type of detergent used in this 
process is very important. The detergent sodium cholate is used to create lipid/detergent micelles 
for use in this process to due sodium cholates ability to be quickly and easily removed from the 
mixture - allowing for plenty of lipid to be present for the membrane protein to surround itself with 
once out of its detergent micelle. 4 mg of sodium cholate was added to 2 mg of lipid and brought 
up to a 1 mL total volume using NaAtm1 Buffer A. This mixture was vortexed and then placed in 
a waterbath sonicator for 30 minutes. The ultimate composition of the lipid mixture used in 
reconstitutions was 2 mg/mL 1:3 (w/w) egg PC: E. coli polar lipid extract, 4 mg/mL sodium 
cholate, and approximately 20 mM Tris, 100 mM NaCl, and 0% DDM.  
 
3.3.1.3 Bio-Beads 
Dry Bio-Beads (Amberlite® XAD-2) were purchased from Bio-Rad. ~15 mL of dry Bio-
Beads were first washed with 100% methanol in a 50 mL conical tube. After inverting multiple 
times, the Bio-Beads were allowed to settle before removal of the methanol. The process was 
repeated using an additional round of 100% methanol, 2 rounds of 95% ethanol, 2 rounds of 
ddH2O, and finally 2 rounds Reconstitution Buffer A. Washed Bio-Beads were stored in a minimal 
volume of Reconstitution Buffer A (enough to prevent beads from drying out) and stored at 4 °C 






3.3.2  Reconstitution methods 
3.3.2.1 Assembly and purification of small-scale reconstitutions 
 As shown in published literature, each integral membrane protein requires an optimized 
ratio of protein-of-interest, scaffolding protein, and lipid. To determine the proper conditions for 
assembly of NaAtm1 nanodiscs, a series of small-scale reconstitutions were prepared and 
analyzed.  
In general, small-scale reconstitutions were approximately 300 µL in volume and prepared 
in 1.5 mL microcentrifuge tubes. Reagents were added in the order of lipid, MSP1D1, 
Reconstitution Buffer A (20 mM Tris-HCl and 150 mM NaCl pH 7.5), and NaAtm1. 50 µL of wet 
Bio-Beads was then added, and the mixture placed on an Adams Nutator at 4 °C overnight.  
 The following day, the reconstitution was centrifuged for 1 minute at maximum speed in a 
microcentrifuge to pellet the Bio-Beads. The supernatant was then applied to a 0.22 µm filter to 
remove aggregates. The sample was injected over a Superdex 200 Increase 10/300 GL sizing 
column at 1 mL/min. Elution fractions were collected for subsequent analysis. 
 
3.4  Reconstitution results 
3.4.1  Identification of multiple species present in reconstitutions 
Initial reconstitutions were created using a 1-3-60 molar ratio of NaAtm1-MSP1D1-lipid 
with a final transporter concentration of 10 µM, as recommended in published protocols [11]. This 
reconstitution yielded three peaks (Figure 3-11) at ~12 mL, ~13.75 mL, and ~15.75 mL. A sample 
of each peak was analyzed using SDS-PAGE (not shown) and it was determined that Peak 1 
contained both NaAtm1 and MSP1D1 while Peaks 2 and 3 contained only MSP1D1. This result 
suggested that the Peak 1 contained NaAtm1 successfully embedded in a nanodisc; however, more 




peak that elutes at ~12 mL elution volume, Peak 2 refers to the peak that elutes at ~13.75 mL 
elution volume, and Peak 3 refers to the peak that elutes at ~15.75 mL elution volume.  
 
 
Figure 3-11. 1-3-60 NaAtm1-MSP1D1-Lipid reconstitution with a final NaAtm1 concentration of 10 µM and a final 
volume of 300 uL.  
 
3.4.1.1 Reconstitution without NaAtm1: 0-3-60 
 To aid in identifying the multiple peaks, different versions of the 1-3-60 reconstitutions 
were prepared with one component removed (i.e. 0-3-60, 1-0-60, 1-3-0) at 5 µM final transporter 
concentration. 
A 0-3-60 NaAtm1-MSP1D1-lipid reconstitution yielded two peaks at the same elution 
volume as Peaks 2 and 3 from the 1-3-60 reconstitution, with no peak at the same elution volume 
as Peak 1. A sample of each peak was analyzed using SDS-PAGE (data not shown), and it was 
determined that both peaks contained only MSP1D1, as expected. This result demonstrated that 
NaAtm1 was a critical component of the species in Peak 1 seen in the 1-3-60 
reconstitution.  Furthermore, this suggested that the Peak 1 did not contain MSP1D1 aggregates, 





Figure 3-12. Size exclusion chromatogram of a 0-3-60 5 µM 300 µL reconstitution. This chromatogram shows two 
peaks that match Peaks 2 and 3 respectively in the 1-3-60 chromatogram (Figure 3-11). 
 
 
3.4.1.2 Reconstitution without MSP1D1: 1-0-60 
 A reconstitution with a molar ratio of 1-0-60 of NaAtm1-MSP1D1-lipid was then created. 
This reconstitution yielded a peak at the void volume, which is most likely a collection of non-
functional masses of NaAtm1 transporters. In the absence of the lipid bilayer enclosed by 
MSP1D1, removal of detergent by Bio-Beads would drive aggregation of the hydrophobic regions 
of NaAtm1. This result implies that MSP1D1 is a critical component of Peak 1 in the 1-3-60 
reconstitution.  
 
Figure 3-13. Size exclusion chromatogram of a 1-0-60 5 µM 300 µL reconstitution. This chromatogram shows a small 
peak at the void volume for the column used. This suggests that in the absence of MSP1D1, NaAtm1 





3.4.1.3 Reconstitution without additional lipids: 1-3-0 
A reconstitution with a molar ratio of 1-3-0 was then created. This reconstitution yielded 
two peaks that matched Peak 1 and Peak 3 in the 1-3-60 reconstitution. This interesting result 
might be due to the presence of a small amount of lipid around both NaAtm1 and MSP1D1 that 
was not removed during purification. The combination of the small lipid stores around each protein 
could be enough to create an intact nanodisc. These observations suggest that lipid is a critical 
factor in Peak 2 but not in Peak 3. This leads to the conclusion that Peak 2 forms only in the 
presence of both MSP1D1 and lipid. In addition, the 0-3-60 reconstitution showed that NaAtm1 is 
not a critical component of Peak 2 or 3. Together, these findings suggest that Peak 2 is empty 
nanodisc and Peak 3 is excess MSP1D1.  
 
 
Figure 3-14. Size exclusion chromatogram of a 1-3-0 5 µM 300 µL reconstitution. This chromatogram shows two peaks 











3.4.2  Conclusion for peak identification in small-scale reconstitutions 
In summary, a 1-3-60 ratio of nanodisc components resulted in three peaks resolved by size 
exclusion chromatography: NaAtm1 successfully reconstituted nanodiscs (Peak 1), empty 




Figure 3-15. A comparison of size exclusion chromatograms of reconstitutions with and without NaAtm1.  
 
3.4.3  Reconstitution optimization 
Once the different species in the initial 1-3-60 reconstitution were identified, the reconstitution 
method was optimized to maximize the yield of NaAtm1 nanodiscs. To accomplish this, three 
different variables were altered: NaAtm1:MSP1D1 molar ratio, NaAtm1:Lipid molar ratio, and 
final NaAtm1 concentration.  
 
3.4.3.1 NaAtm1:MSP1D1 optimization 
Five reconstitutions were created using different molar ratios of NaAtm1:MSP1D1 (1-3-
60, 1-4-60, 1-5-60, 1-6-80, and 1-7-80 NaAtm1-MSP1D1-Lipid). Each reconstitution was 
analyzed using size exclusion chromatography and overlaid for comparison (Figure 3-16). These 




to 1:4, but for higher ratios (1:5-1:7) there was no appreciable difference in Peak 1 height. It was 
also observed that as the molar ratio of NaAtm1:MSP1D1 increased, both Peak 2 and Peak 3 
increased as well. This suggests that at a molar ratio of 1:4, the reaction has gone to completion 
and that NaAtm1 is now the limiting reagent. From this conclusion, the molar ratio 1:4 
NaAtm1:MSP1D1 was chosen for future reconstitutions.  
 
 
Figure 3-16. Comparison of reconstitutions created using different molar ratios of NaAtm1:MSP1D1. 
 
3.4.3.2 NaAtm1:Lipid optimization 
 Four reconstitutions were created using different molar ratios of NaAtm1:Lipid (1-5-50, 1-
5-60, 1-5-80, and 1-5-120 NaAtm1-MSP1D1-Lipid). The NaAtm1:MSP1D1 molar ratio of 1:5 
was chosen instead of 1:4 to increase the prominence of Peak 3 within this experiment. By using 
a ratio that produces a more noticeable Peak 3, the resulting change in the peak is visible while 
changing the NaAtm1:Lipid ratio. Analysis via size exclusion chromatography showed that the 




there was no appreciable difference in Peak 1 height. It was also observed that as the molar ratio 
of NaAtm1:lipid increased, the Peak 2 increased while Peak 3 decreased.  
These data suggest that as the amount of lipid increases, the formation of nanodisc is driven 
to completion, dictated by the amount of scaffolding protein. When NaAtm1 is the limiting reagent 
for primary product formation (full nanodisc), the secondary product (empty nanodisc) 
accumulates. This data is consistent with the initial conclusions (Section 3.4.1) that Peak 2 contains 
empty nanodisc and Peak 3 contains excess MSP1D1.  For the optimization of these 
reconstitutions, the goal was to maximize the NaAtm1 nanodiscs identified in Peak 1, while 
minimizing the empty nanodiscs found in of Peak 2. The results suggest that these parameters are 
best met with a molar ratio 1:60 NaAtm1:Lipid.  
 










3.4.3.3 Final NaAtm1 concentration optimization 
 The last condition that was explored was the final NaAtm1 concentration of all of the 
components at a fixed ratio, which was necessary for scaling up to larger amounts of nanodiscs. 
Reconstitutions of 1-5-80 were prepared at 5 µM, 10 µM, 15 µM, and 20 µM NaAtm1. For 
example, the 15 µM sample would consist of 15 µM NaAtm1, 75 µM MSP1D1, and 1200 µM 




Figure 3-18. Comparison of reconstitutions created using different final concentrations of NaAtm1. 
 
 
As expected, the height of all peaks were directly correlated with final protein 
concentration. With multiple repeats, however, it was observed that reconstitutions at high 
concentrations were less reproducible than at lower concentrations. High concentration 
reconstitutions often resulted in extremely low amounts of total recovered material (data not 




aggregation, which would be removed by routine sample filtration before the analysis on the size 
exclusion column. Due to the difficulty in reproducibility at higher final transporter concentrations, 
5 µM final NaAtm1 concentration was used for subsequent reconstitutions.  
 
3.4.4  Optimization conclusion 
 The results of these experiments show that an optimized reconstitution for NaAtm1 in 
MSP1D1 using 1:3 PC:E lipid consists of a molar ratio of 1-4-60 with a final NaAtm1 
concentration of 5 µM.  
 
3.5  Determining the stoichiometry of nanodiscs using densitometry 
Once the reconstitution ratio was optimized, the resulting purified nanodiscs were analyzed 
to determine the molar ratio of NaAtm1 to MSP1D1. This was necessary for two reasons: (1) to 
ensure that each nanodisc contained only one NaAtm1, and (2) to create a method for 
quantification of nanodiscs via absorbance spectroscopy.  
To accomplish this, nanodiscs were analyzed by SDS-PAGE and stained using the 
fluorescent protein gel stain SYPRO Ruby, which is highly quantitative and sensitive to low 
protein concentrations (Figure 3-19). For these densitometry experiments, a standard curve was 
generated for both NaAtm1 and MSP1D1 based on the molecular weight of each (135361 g/mol 
and 24793 g/mol, respectively). The protein solutions used to prepare the standard curve were 
quantified using the calculated extinction coefficient of each (152,640 M-1 cm-1 and 24130 M-1 
cm-1, respectively). Serial dilutions of the purified NaAtm1 nanodiscs samples were prepared 
identically, with SDS and DTT present to denature and separate protein complexes. As seen in 





Figure 3-19. SDS-PAGE analysis using SYPRO Ruby stain.  
 
The intensities of the protein bands in the “NaAtm1 Standard” and “MSP1D1 Standard” 
were quantified to create a standard curve for each protein (Figure 3-20). The standard curve for 
NaAtm1 was then used to determine how much NaAtm1 was present in each lane of the 
“Reconstitution” serial dilutions (Figure 3-19, “Reconstitution” top protein band) while the 
MSP1D1 standard curve was used to determine how much MSP1D1 was present in each lane of 
the “Reconstitution” serial dilutions (Figure 3-19, “Reconstitution” bottom protein band). 
 
 








The amount of each component (NaAtm1 and MSP1D1) in each lane was then compared 
to determine the NaAtm1:MSP1D1 ratio (w/w). The average NaAtm1:MSP1D1 ratio (w/w) over 
multiple lanes was 2.75:1 (Table 3-1). This experimentally determined w/w ratio is remarkably 
similar to the ideal calculated w/w ratio of 2.73:1, which corresponds to a 1:2 mol ratio of 
NaAtm1:MSP1D1. This result strongly suggests that the nanodiscs produced during this 
experiment contain a molar ratio of 1:2 NaAtm1:MSP1D1.   
Label: 
NaAtm1 calculated using 
Standards (µg): 
MSP1D1 calculated using Standards (µg):
Ratios:
Lane 19 1.645 0.595 2.766
Lane 20 1.618 0.592 2.733
Lane 21 1.581 0.577 2.740
Lane 22 1.290 0.470 2.744
Lane 23 1.137 0.418 2.718
Lane 24 0.924 0.308 2.997
Lane 25 0.711 0.253 2.810
Lane 26 0.503 0.201 2.499
  Average: 2.751
 
Table 3-1. Representative comparison of component parts quantified by densitometry 
 
3.6  Quantification of NaAtm1 nanodiscs via absorbance spectroscopy 
 Based on the results of the densitometry analysis above, a simple “correction factor” could 
be calculated to allow for the quantification of NaAtm1 nanodiscs via absorbance measurement at 
280 nm. Using samples containing the same amount of NaAtm1 transporter, the absorbance of 
NaAtm1 in detergent micelles was compared to that NaAtm1 in nanodiscs. It was observed that 
the nanodisc samples showed a consistent 1.33-fold increase in absorbance when compared to 
detergent-solubilized samples. Thus, using the calculated extinction coefficient of NaAtm1 alone, 




absorbance value corresponding to 500 nM NaAtm1 in detergent would translate into 667 nM 
NaAtm1 in nanodisc. This correction factor will be appropriate for quantification of samples for 
functional assays.  
 
3.7  Transition to an IMAC-based purification method 
  Unfortunately, the results seen in table 3-1 were not consistent across multiple tests. A 
higher-than-expected result with a w/w ratio of ~1:3 was often seen. The most likely cause of this 
in consistency was the presence of empty nanodisc (Peak 2) that was unable to be separated from 
Peak 1 using size exclusion chromatography. To rectify this issue, size exclusion chromatography 
was replaced by an IMAC-based purification method for the isolation of NaAtm1 nanodiscs 
following reconstitution.  
To isolate NaAtm1 nanodiscs from empty nanodiscs, the His-tag on MSP1D1 can be 
removed via proteolytic cleavage. Using this strategy, NaAtm1 nanodiscs could bind to Ni-NTA 
resin due to the His-tag on NaAtm1, but empty discs would remain unbound and removed from 






Figure 3-21. IMAC purification with MSP1D1 containing His-tag produces two products, both with His-tag. Cleavage of 
the MSP1D1 His-tag results in one His-tagged product and one tagless product.  
 
 
To remove the His-tag on MSP1D1, we took advantage of a TEV proteolytic cleavage site 
between the His-tag and MSP1D1 coding sequence.  Due to the high cost of commercially 
available TEV, and the need for large quantities, we decided to express and purify TEV in-house. 
Once available, the TEV: MSP1 reaction ratio was optimized, and subsequent purification of His-
tag-cleaved was performed.  
 
3.8 Optimization of His-tag cleavage by TEV protease 
TEV protease was purified as described in Chapter 2. Once purified, an initial test of 
protease activity was conducted using MSP1D1. Manufacturers recommend 1 µg of commercially 
available TEV protease for every 15 µg of target protein, which translates into approximately a 




efficient cleavage, four reactions were created with varying amounts of MSP1D1. In these 
reactions, 1 µg of TEV protease was applied to 15 µg, 50 µg, 100 µg, and 200 µg of MSP1D1. 
Samples of each reaction were taken immediately upon mixing and quickly flash frozen in liquid 
nitrogen for analysis. The cleavage reactions were then allowed to proceed overnight at 4 °C. The 
next day, samples were taken and analyzed via SDS-PAGE (Figure 3-22).   
 
 
Figure 3-22. Cleavage reactions with varying ratios of TEV: MSP1D1.  T0 = 0 hours, T1 = 24 hours. 
 
The results showed that after 24 hours, both the 1:15 (w/w) and 1:50 (w/w) samples showed 
complete cleavage of MSP1D1 (removal of upper band) while the 1:100 (w/w) showed almost 
complete cleavage and the 1:200 (w/w) showed incomplete cleavage of MSP1D1 (presence of 
upper band). From this test it was determined that using 1:50 (w/w) was the best ratio to use for 
future reactions.  
 
3.9 Preparation of His-tag-cleaved MSP1D1  
After determining the proper ratio of TEV protease to MSP1D1, a method was created to 
purify isolate cleaved MSP1D1 from uncleaved MSP1D1.  
Following cleavage for 24 hours at 4 °C, reactions were purified by IMAC using Ni-NTA 
resin.  In this case however, the isolation process was somewhat unconventional. In most cases, 
the target protein contains the His-tag and is retained on the column. A low concentration of 




also results in the loss of some target protein as well. This small loss of His-tagged target protein 
is preferable to having contaminants in the final product. The His-tagged target protein is then 
eluted at higher concentration imidazole, typically 350-400 mM. This general procedure was 
applied to the purification of NaAtm1, MSP1D1, and TEV protease. In contrast, for purification 
of the cleaved MSP1D1, the contaminating proteins are retained on the column, and the target 
protein is collected in the “flow through” (Figure 3-23). 
 
Figure 3-23. Normal IMAC vs Reverse IMAC 
  
To optimize the final purity of the “flow through” which contains the target protein, the 
imidazole level needs to be low enough that all unwanted his-tagged contaminants are retained on 
the column, even at the loss of a small amount of target protein due to non-specific binding. To 
determine the optimum imidazole concentration, 10 mM imidazole, 15 mM imidazole, and no 
imidazole were added to cleavage reactions. Once the “flow through” was complete, the remaining 




elution peaks were analyzed for the presence of His-tag cleaved MSP1D1. The results showed that 
an imidazole concentration of 15 mM was ideal to prevent non-specific binding of cleaved 
MSP1D1, and also retain the contaminant tagged MSP1D1 on the column. Ultimately, a large 
amount of tagless MSP1D1 was recovered for subsequent reconstitutions. 
 
 
Figure 3-24. Comparison of His-tag separations using 0 mM, 10 mM, and 15 mM imidazole. For each run a constant 
concentration of noted imidazole was using during the “flow through”. Once complete, 350 mM imidazole was used 
during an elution phase for analysis purposes.  
 
 
3.10  Purification of NaAtm1 in MSP1D1 nanodisc using IMAC 
Once purified, His-tag-cleaved MSP1D1 was used in the creation of large-scale 
reconstitutions using the optimized molar ratio of 1-4-60 NaAtm1-MSP1D1-Lipid with a final 








3.10.1 Assembly and purification of large-scale reconstitutions 
 Large-scale reconstitutions were created using the same procedure as described in section 
3.3.2.1 with minor changes. These changes included replacing His-tagged MSP1D1 with His-tag-
cleaved MSP1D1, increasing the final volume from 300 µL to 1 mL, and increasing the Eppendorf 
tube from 1.5 mL to 5 mL.  It was normal for three to five 1 mL reconstitutions to be created at 
once.  
Following overnight incubation, reconstitutions were centrifuged at 3,500 rpm for 2 
minutes to pellet the Bio-Beads. The reconstitution mixtures were then pooled and filtered using a 
0.22 µm filter to remove aggregates. Imidazole was added to the filtered mixture to create a final 
concentration of 15 mM. The sample was then flowed over a 1 mL HisTrap HP (Ni-NTA) column, 
using the column in the traditional way to capture His-tagged full nanodisc (Figure 3-25). The 
target protein was eluted and fractions collected. Pooled fractions were then concentrated to under 
1.5 mL using a 100kDa concentrator before being injected over a 5 mL HiTrap Desalting column 
to remove imidazole.  Given this new method of purification, no size exclusion chromatography 
was necessary. IMAC fractions were collected, aliquoted, and flash frozen in liquid nitrogen for 






Figure 3-25. IMAC chromatogram of nanodisc separation using a 1 mL HisTrap HP Ni-NTA column. 
 
3.10.2 Analysis of large-scale reconstitutions 
A 500 µL sample of the desalted protein was thawed and flowed over a Superdex 200 
Increase 10/300 GL size exclusion column for confirmation of a single species. The results showed 
a single peak around 12.1 mL (Figure 3-26). When compared to a small-scale reconstitution of 1-
4-60 NaAtm1-MSP1D1-Lipid 300 µL, Peak 1 in the small-scale reconstitution overlaps nicely 
with the single peak from the IMAC purified nanodisc, and the contaminating Peaks 2 and 3 are 
completely removed (Figure 3-27). This suggests that the IMAC purification process works well 



















 In this Chapter I have described multiple structures that can be used to mimic a lipid bilayer 
- the natural environment of NaAtm1 and ABC transporters in general. These structures include 
detergent micelles, liposomes, and nanodiscs. Nanodiscs were chosen for studies with NaAtm1 
due to their relative robustness compared to liposomes and their capacity to more closely mimic a 
lipid bilayer than detergent micelles. Through iterative modifications of both reconstitution 
component ratios and purification methods, I have created a method for the assembly of NaAtm1-
MSP1D1 complexed nanodiscs. Importantly, this system is scalable to the larger quantities needed 
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Preliminary Kinetic Assays and Future Work 
 
4.1 Introduction 
The ultimate goal of our NaAtm1 studies is to understand the molecular mechanism by 
which this protein drives transport of substrates across lipid membranes. The incorporation of 
NaAtm1 into nanodiscs is an important foundational step in this pursuit. While the structural 
studies in detergent have provided a wealth of information on NaAtm1, careful kinetic and 
thermodynamic assays in lipidic environments will significantly further our understanding of its 
mechanism. Questions include: what is the natural substrate for NaAtm1, how quickly does 
NaAtm1 transport this substrate, and what is the affinity for this substrate? Using both DDM-
solubilized NaAtm1 and the newly-formed NaAtm1 nanodiscs, two preliminary experiments were 
conducted.  
 
4.2  Kinetic assays 
 First, the rate of ATP hydrolysis was measured as a function of ATP concentration. This 
canonical experiment provides three key parameters when fit to a Michaelis-Menten model: (1) 
the turnover number (kcat), which is the rate constant for ATP hydrolysis at saturating concentration 
(2) the Michaelis constant (Km), which is the concentration of the substrate at which the turnover 
rate is half the calculated maximum velocity, and (3) the Hill coefficient (n), which is a measure 
of cooperativity between the two ATP sites.  Using the system described in Chapter 2, the activity 
of detergent-solubilized NaAtm1 was monitored in the absence of substrate. Best-fit values were 
kcat = 14.42 min-1, Km = 36 µM, and n = 1.36. The latter value suggests that the binding of the first 




amongst ABC transporters. This experiment was consistent with published parameters, which had 
a slightly lower turnover rate of 8.8 ± 0.8 min-1 at room temperature, while our data was collected 
at 37 °C. 
A few months later, however, the result was startlingly different, with a turnover rate of 
~54 min-1. (Figure 4-1). During the troubleshooting process, all reagents were made fresh, 
including the preparation of NaAtm1, however the results remained consistently 4-fold higher. It 
is still unclear what has caused this dramatic change in activity and what it means for further kinetic 
assays.  
 
Figure 4-1. Comparison of the kobs for an initial assay (circle) and subsequent experiments (triangle). 
 
Next, the kinetic activity of NaAtm1 nanodiscs was directly compared to NaAtm1 in 
detergent. Surprisingly, the results were identical. Most ABC transporters show drastic inhibition 
of uncoupled hydrolysis upon insertion into a lipid bilayer, and thus further experimentation will 












Figure 4-2. A) Kinetic assay for NaAtm1 in detergent. B) Kinetic assay for NaAtm1 in nanodisc. The kcat, Km, and n for 
both assays are startlingly similar. 
 
 
4.3  Future work 
 While my time at USF is at an end, this project still has many more avenues of inquiry. 
Now that methods of purification and nanodisc assembly have been created, there is a solid 
foundation for further work.  Types of future experiments include further kinetic assays combined 
with mutational analyses, and EPR or fluorescence spectroscopy tests. 
 
4.3.1  Further kinetic assays 
 Detailed kinetic studies will yield important insights into the mechanism of NaAtm1, such 
as the coordination between the two NBDs, substrate preferences, and the efficiency of transport. 
While NaAtm1 mutants have not been discussed in this thesis, mutant constructs of NaAtm1 have 
been created to help answer these questions. These are K400A (Walker A mutant to remove ability 
to bind ATP), E523Q (Walker B mutant to remove ability to hydrolyze ATP), and K142Q (an 
equivalent of R216Q [1] that should prohibit binding of the substrate GSSG). The incorporation 
 kcat (min-1) Km (µM) n 
NaAtm1 in detergent: 54.19 238 1.896 




of these mutants into kinetic assays, in addition to comparisons between detergent micelles and 
nanodiscs, will allow us to further explore NaAtm1 function. 
 
4.3.2 Detection of conformational changes 
 Currently, there is only one high-resolution crystal structure of NaAtm1, much like a single 
snapshot of the enzyme in motion. To detect conformational changes that take place during the 
transport cycle, a cysteine mutation was introduced which enables fluorescent labeling at the 
reactive thiol side chain (NaAtm1 does not contain any naturally-occurring cysteines). Residue 
S526 was selected as a labeling site because it is located in the NBDs, which is believed to move 
substantially and is within the critical distance needed for use in fluorescence resonance energy 
transfer (FRET) experiments. This technique will allow us to monitor changes in the relative 
distance between the NBDs as a function of nucleotide-state and substrate binding. We could also 
compare the flexibility of the protein in detergent micelles versus lipid bilayers. Furthermore, spin-
labeling of the cysteine may allow us to follow these motions using electron paramagnetic 
resonance spectroscopy, another technique that has been commonly used to detect conformational 
changes in proteins. Lastly, introduction of cysteine residues at other locations will allow us to 












4.4  Conclusion 
 This thesis has detailed ABC transporters, their diversity, and their importance to human 
health. It focuses on the ABCB-type importer NaAtm1 - an exporter shown to export the heavy 
metals silver and mercury in vivo [2]. The main goal of this work was to create a robust lipidic 
environment in which to study NaAtm1. This mimetic environment came in the form of nanodiscs 
- a self-assembling lipid bilayer disc that surrounds NaAtm1.  
To accomplish this, the purification of NaAtm1 and the scaffolding protein MSP1D1 were 
conducted and optimized. Through careful and systematic modification of the nanodisc 
components, an ideal reconstitution ratio of NaAtm1:MSP1D1:lipids was determined, and the 
proper stoichiometry of 2 MSP1D1 per 1 NaAtm1 was verified. Additionally, an improved method 
for the enrichment of NaAtm1 nanodiscs was developed based on affinity chromatography. This 
work lays the foundation for future studies on elucidating the mechanism of NaAtm1 in a lipidic 
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